CLDF Title
Home | Contact Us | Bookmark
 
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Slide Library Abstract Library Conference Highlights
 
HCC | Abstract Library
Abstract Library
 
 
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
 
 
  1. Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies
    Della Corte C, Aghemo A, Colombo M. World J Gastroenterol. 2013 Mar 7;19(9):1359-71. doi: 10.3748/wjg.v19.i9.1359.


  2. Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma
    Shukla R, Upton KR, Muñoz-Lopez M, Gerhardt DJ, Fisher ME, Nguyen T, Brennan PM, Baillie JK, Collino A, Ghisletti S, Sinha S, Iannelli F, Radaelli E, Dos Santos A, Rapoud D, Guettier C, Samuel D, Natoli G, Carninci P, Ciccarelli FD, Garcia-Perez JL, Faivre J, Faulkner GJ. Cell. 2013 Mar 28;153(1):101-11. doi: 10.1016/j.cell.2013.02.032.


  3. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients
    Akbulut S, Kayaalp C, Yilmaz M, Ince V, Ozgor D, Karabulut K, Eris C, Toprak HI, Aydin C, Yilmaz S. World J Gastroenterol. 2013 Mar 14;19(10):1625-31. doi: 10.3748/wjg.v19.i10.1625.


  4. Pressure Wire Assessment of Hemodynamic Alterations after Chemoembolization of Hepatocellular Carcinoma
    Borowski AM, Frangos A, McCann JW, Brown DB. Acad Radiol. 2013 Mar 25. pii: S1076-6332(13)00102-5. doi: 10.1016/j.acra.2013.02.005. [Epub ahead of print]


  5. Clinicopathologic characteristics and prognoses for multicentric occurrence and intrahepatic metastasis in synchronous multinodular hepatocellular carcinoma patients
    Li SL, Su M, Peng T, Xiao KY, Shang LM, Xu BH, Su ZX, Ye XP, Peng N, Qin QL, Chen DF, Chen J, Li LQ. Asian Pac J Cancer Prev. 2013;14(1):217-23.


  6. Isolated fat-containing pancreatic metastasis from hepatocellular carcinoma
    Nishiofuku H, Marugami N, Tanaka T, Anai H, Maeda S, Masada T, Takano M, Mitoro A, Kichikawa K. Jpn J Radiol. 2013 Mar 29. [Epub ahead of print]


  7. Hepatocellular carcinoma likelihood on MRI exams: evaluation of a standardized categorization system
    Petruzzi N, Mitchell D, Guglielmo F, O'Kane P, Deshmukh S, Roth C, Shortt C, Balfour S, Parker L. Acad Radiol. 2013 Jun;20(6):694-8. doi: 10.1016/j.acra.2013.01.016. Epub 2013 Mar 28.


  8. Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study
    Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S. J Gastroenterol. 2013 Mar 30. [Epub ahead of print]


  9. Influence of percutaneous local therapy for hepatocellular carcinoma on gastric function
    Kobayashi M, Kinekawa F, Matsuda K, Fujihara S, Nishiyama N, Nomura T, Tani J, Miyoshi H, Kobara H, Deguchi A, Yoneyama H, Mori H, Masaki T. World J Gastroenterol. 2013 Mar 14;19(10):1618-24. doi: 10.3748/wjg.v19.i10.1618.


  10. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages
    Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E. Biomed Res Int. 2013;2013:187204. doi: 10.1155/2013/187204. Epub 2012 Dec 30.


  11. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma - A systematic review
    Chan DL, Morris DL, Chua TC. Surg Oncol. 2013 Mar 24. pii: S0960-7404(13)00027-3. doi: 10.1016/j.suronc.2013.02.009. [Epub ahead of print]


  12. Implication of polymorphisms in DNA repair genes in prognosis of hepatocellular carcinoma
    Yue AM, Xie ZB, Guo SP, Wei QD, Yang XW.


  13. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values
    Jin GZ, Dong H, Yu WL, Li Y, Lu XY, Yu H, Xian ZH, Dong W, Liu YK, Cong WM, Wu MC. BMC Cancer. 2013 Mar 27;13:161. doi: 10.1186/1471-2407-13-161.


  14. Serum alpha-fetoprotein level independently predicts post-transplantation survival in patients with hepatocellular carcinoma
    Berry K, Ioannou GN. Liver Transpl. 2013 Mar 27. doi: 10.1002/lt.23652. [Epub ahead of print]


  15. Aflatoxins, hepatocellular carcinoma and public health
    Magnussen A, Parsi MA. World J Gastroenterol. 2013 Mar 14;19(10):1508-12. doi: 10.3748/wjg.v19.i10.1508.


  16. Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer
    Darvesh AS, Bishayee A. Nutr Cancer. 2013;65(3):329-44. doi: 10.1080/01635581.2013.767367.


  17. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma
    Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez-Peralvarez ML, Germani G, Davies N, Yu D, Luong TV, Dhillon AP, Thorburn D, Patch D, O'Beirne J, Meyer T, Burroughs AK. Liver Int. 2013 Feb 20. doi: 10.1111/liv.12144. [Epub ahead of print]


  18. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China
    Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N, Dong J, Yao L, Tang W. Biosci Trends. 2013 Feb;7(1):1-6.


  19. Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis
    Hosonuma K, Sato K, Yanagisawa M, Kakizaki S, Takagi H, Hirato J, Mori M. Gastroenterol Res Pract. 2013;2013:168012. doi: 10.1155/2013/168012. Epub 2013 Feb 25.


  20. Inflammation induced hepatocellular carcinoma is dependent on CCR5
    Barashi N, Weiss ID, Wald O, Wald H, Beider K, Abraham M, Klein S, Goldenberg D, Axelrod J, Pikarsky E, Abramovitch R, Zeira E, Galun E, Peled A. Hepatology. 2013 Mar 21. doi: 10.1002/hep.26403. [Epub ahead of print]


  21. Direct transformation of lung microenvironment by interferon-? treatment counteracts growth of lung metastasis of hepatocellular carcinoma
    Zhuang PY, Shen J, Zhu XD, Zhang JB, Tang ZY, Qin LX, Sun HC. PLoS One. 2013;8(3):e58913. doi: 10.1371/journal.pone.0058913. Epub 2013 Mar 18.


  22. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis
    Yu J, Ma Q, Zhang B, Ma R, Xu X, Li M, Xu W, Li M. Sci China Life Sci. 2013 Mar;56(3):234-9. doi: 10.1007/s11427-013-4451-y. Epub 2013 Mar 23.


  23. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker
    Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. PLoS One. 2013;8(3):e59459. doi: 10.1371/journal.pone.0059459. Epub 2013 Mar 18.


  24. Changes in plasma ghrelin and serum leptin levels after Cisplatin-based transcatheter arterial infusion chemotherapy for hepatocellular carcinoma
    Matsumura T, Arai M, Yoshikawa M, Sudo K, Nakamura K, Katsuno T, Kanai F, Yamaguchi T, Yokosuka O. ISRN Gastroenterol. 2013;2013:415450. doi: 10.1155/2013/415450. Epub 2013 Mar 7.


  25. Total Tumor Volume Is a Better Marker of Tumor Burden in Hepatocellular Carcinoma Defined by the Milan Criteria
    Lee YH, Hsia CY, Hsu CY, Huang YH, Lin HC, Huo TI. World J Surg. 2013 Mar 7. [Epub ahead of print]


  26. Prospective Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: An Asian Cooperative Study between Japan and Korea
    Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T; Japan Interventional Radiology in Oncology Study Group (JIVROSG), and Korea Interventional Radiology in Oncology Study Group (KIVROSG). J Vasc Interv Radiol. 2013 Apr;24(4):490-500. doi: 10.1016/j.jvir.2013.01.003. Epub 2013 Mar 7.


  27. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2 and CDC42
    Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y, Zhuang SM. Hepatology. 2013 Mar 6. doi: 10.1002/hep.26373. [Epub ahead of print]


  28. Adjuvant Hepatic Intra-arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Trial
    Chung AY, Ooi LL, Machin D, Tan SB, Goh BK, Wong JS, Chen YM, Li PC, Gandhi M, Thng CH, Yu SW, Tan BS, Lo RH, Htoo AM, Tay KH, Sundram FX, Goh AS, Chew SP, Liau KH, Chow PK, Tay KH, Tan YM, Cheow PC, Ho CK, Soo KC. World J Surg. 2013 Mar 6. [Epub ahead of print]


  29. Liver injury and disease pathogenesis in chronic hepatitis C
    Yamane D, McGivern DR, Masaki T, Lemon SM. Curr Top Microbiol Immunol. 2013;369:263-88. doi: 10.1007/978-3-642-27340-7_11.


  30. Correlations between the time-intensity parameters of contrast-enhanced ultrasound and clinical prognosis of hepatocellular carcinoma
    Yang YL, Yang RJ, Liu X, Liu J, Chao LJ, Duan YY. Clin Imaging. 2013 Mar-Apr;37(2):308-12. doi: 10.1016/j.clinimag.2012.06.002. Epub 2012 Jul 15.


  31. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J Hepatol. 2013 Mar 4. pii: S0168-8278(13)00144-X. doi: 10.1016/j.jhep.2013.02.022. [Epub ahead of print]


  32. Atypical Hepatic Resection Technique for Hepatocellular Carcinoma Using Radiofrequency Habib? 4X Device
    Vlad N, Lupa?cu C, D?nil? N, Georgescu S, Moldovanu R, Târcoveanu E. Chirurgia (Bucur). 2013 Jan-Feb;108(1):51-5.


  33. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region
    Kim MN, Kim BK, Han KH. J Gastroenterol. 2013 Mar 6. [Epub ahead of print]


  34. Evaluation of the Clinical Features of HCC following Hepatectomy for Different Stages of HCC
    Ma C, Chi M, Su H, Cheng X, Chen L, Kan Y, Wei W, Huang X, Li Y, Li L, Lin K, Huang Y, Wu Y, Huang X, Huang A, Liu J. Hepatogastroenterology. 2012 Oct;59(119):2104-11. doi: 10.5754/hge12109.


  35. The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
    Yeh CB, Hsieh MJ, Lin CW, Chiou HL, Lin PY, Chen TY, Yang SF. PLoS One. 2013;8(2):e56661. doi: 10.1371/journal.pone.0056661. Epub 2013 Feb 20.


  36. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1
    Zhai JM, Yin XY, Lai YR, Hou X, Cai JP, Hao XY, Liang LJ, Zhang LJ. Cancer Chemother Pharmacol. 2013 Feb 23. [Epub ahead of print]


  37. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability
    Køstner AH, Sorensen M, Olesen RK, Grønbæk H, Lassen U, Ladekarl M. ScientificWorldJournal. 2013;2013:931972. doi: 10.1155/2013/931972. Epub 2013 Jan 29.


  38. A Systematic Review of Radiofrequency Ablation versus Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma up to 3 cm
    Shen A, Zhang H, Tang C, Chen Y, Wang Y, Zhang C. J Gastroenterol Hepatol. 2013 Feb 21. doi: 10.1111/jgh.12162. [Epub ahead of print]


  39. Is hepatic resection for recurrent or persistent hepatocellular carcinoma justified?
    Kishi Y, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguch T. Hepatogastroenterology. 2012 Oct;59(119):2255-9. doi: 10.5754/hge10505.


  40. Characteristics and Surgical Outcome of HCC Patients with Low Platelet Count
    Kondo K, Chijiiwa Y, Otani K, Kai M, Ohuchida J, Chijiiwa K. Hepatogastroenterology. 2012 Oct;59(119):2269-72. doi: 10.5754/hge10649.


  41. Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic Acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the symposium of the 48th annual meeting of the liver cancer study group of Japan
    Kudo M, Matsui O, Sakamoto M, Kitao A, Kim T, Ariizumi S, Ichikawa T, Kobayashi S, Imai Y, Izumi N, Fujinaga Y, Arii S. Oncology. 2013;84 Suppl 1:21-7. doi: 10.1159/000345885. Epub 2013 Feb 20.


  42. Prognotic impact of serum follistatin in patients with hepatocellular carcinoma
    Tomoda T, Nouso K, Miyahara K, Kobayashi S, Kinugasa H, Toyosawa J, Hagihara H, Kuwaki K, Onishi H, Nakamura S, Ikeda F, Miyake Y, Shiraha H, Takaki A, Yamamoto K. J Gastroenterol Hepatol. 2013 Feb 22. doi: 10.1111/jgh.12167. [Epub ahead of print]


  43. The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma
    Kim JM, Kwon CH, Joh JW, Park JB, Ko JS, Lee JH, Kim SJ, Park CK.


  44. Hepatocellular carcinoma after ablation: The imaging follow-up scheme
    Liu LN, Xu HX, Zhang YF, Xu JM. World J Gastroenterol. 2013 Feb 14;19(6):797-801. doi: 10.3748/wjg.v19.i6.797.


  45. Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study
    Cillo U, Vitale A, Dupuis D, Corso S, Neri D, D'Amico F, Gringeri E, Farinati F, Vincenzi V, Zanus G. PLoS One. 2013;8(2):e57249. doi: 10.1371/journal.pone.0057249. Epub 2013 Feb 21.


  46. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?
    Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L; Bologna Liver Oncology Group (BLOG). J Vasc Interv Radiol. 2013 Apr;24(4):509-17. doi: 10.1016/j.jvir.2012.12.013. Epub 2013 Feb 18.


  47. Surveillance for Hepatocellular Carcinoma: How Can We Do Better?
    Hassett M, Yopp AC, Singal AG. Am J Med Sci. 2013 Feb 19. [Epub ahead of print]


  48. Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells
    Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U. Hepatology. 2013 Feb 19. doi: 10.1002/hep.26328. [Epub ahead of print]


  49. An Increase in Lesion Density can Predict Lower Local Recurrence after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
    Imai N, Katano Y, Kuzuya T, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Goto H. Hepatogastroenterology. 2013 Feb 20;60(127). doi: 10.5754/hge121229. [Epub ahead of print]


  50. A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL & AASLD Recommendations?: An Observational Study of the HCC East-West Study Group
    Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M. Ann Surg. 2013 Feb 19. [Epub ahead of print]


  51. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma
    Chan AC, Cheung TT, Fan ST, Chok KS, Chan SC, Poon RT, Lo CM. Ann Surg. 2013 Apr;257(4):686-92. doi: 10.1097/SLA.0b013e3182822c02.CLD_HCC_Kim03122013-110623|Outcomes of Patients with Elevated ?-Fetoprotein Level and Initial Negative Findings at MR Imaging~Kim BS, Hayashi PH, Kim SH, Angthong W, Srirattanapong S, Woosley JT, Semelka RC. Radiology. 2013 Feb 7. [Epub ahead of print]


  52. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis
    Wong GL, Chan HL, Mak CH, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Hepatology. 2013 Feb 6. doi: 10.1002/hep.26301. [Epub ahead of print]


  53. Lack of association between genetic polymorphisms in cytokine genes and tumor recurrence in patients with hepatocellular carcinoma undergoing transplantation
    Wu LM, Zhou L, Xu J, Wei BJ, Cheng J, Xu X, Xi B, Xie HY, Zheng SS. Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):54-9.


  54. Treatment of Liver Transplant Graft-Versus-Host Disease With Antibodies Against Tumor Necrosis Factor-?
    Blank G, Li J, Kratt T, Handgretinger R, Königsrainer A, Nadalin S. Exp Clin Transplant. 2013 Feb;11(1):68-71.


  55. Clinical analysis of recurrent hepatocellular carcinoma after living donor liver transplantation
    Yoon YC, Hong TH, You YK, Kim DG. Clin Transplant. 2013 Feb 5. doi: 10.1111/ctr.12090. [Epub ahead of print]


  56. Postoperative peg-interferon plus ribavirin associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma
    Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Hepatology. 2013 Feb 6. doi: 10.1002/hep.26300. [Epub ahead of print]


  57. Risk factors of poor prognosis and portal vein tumor thrombosis after curative resection of solitary hepatocellular carcinoma
    Zhou L, Rui JA, Wang SB, Chen SG, Qu Q. Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):68-73.


  58. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
    El-Gazzaz G, Sourianarayanane A, Menon KN, Sanabria J, Hashimoto K, Quintini C, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F. Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):34-41.


  59. New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
    Lencioni R. Clin Cancer Res. 2013 Mar 5. [Epub ahead of print]


  60. Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements
    Kogut MJ, Chewning RH, Harris WP, Hippe DS, Padia SA. J Vasc Interv Radiol. 2013 Mar;24(3):326-31. doi: 10.1016/j.jvir.2012.11.019. Epub 2013 Feb 4.


  61. Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements
    Kogut MJ, Chewning RH, Harris WP, Hippe DS, Padia SA. J Vasc Interv Radiol. 2013 Mar;24(3):326-31. doi: 10.1016/j.jvir.2012.11.019. Epub 2013 Feb 4.


  62. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update
    Kew MC. J Viral Hepat. 2013 Mar;20(3):149-57. doi: 10.1111/jvh.12043. Epub 2012 Dec 26.


  63. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study
    Borzio M, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, Francica G, Salvagnini M, Marignani M, Salmi A, Farinati F, Carella A, Pedicino C, Dionigi E, Fanigliulo L, Cazzaniga M, Ginanni B, Sacco R. Future Oncol. 2013 Feb;9(2):283-94. doi: 10.2217/fon.12.183.


  64. A Combination of ?-Fetoprotein and Des-?-Carboxy Prothrombin Is Superior in Detection of Hepatocellular Carcinoma
    Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Gerken G, Schlaak JF. Digestion. 2013 Feb 8;87(2):121-131. [Epub ahead of print]


  65. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma
    Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. BMC Cancer. 2013 Feb 15;13:78. doi: 10.1186/1471-2407-13-78.


  66. Suppression of KIF14 expression inhibits hepatocellular carcinoma progression and predicts favorable outcome
    Yang T, Zhang XB, Zheng ZM. Cancer Sci. 2013 Feb 18. doi: 10.1111/cas.12128. [Epub ahead of print]


  67. Recurrence prediction of hepatocellular carcinoma after liver transplantation by ischemia time and tumor characteristics
    Nagai S, Facciuto M, Mori S, Ninomiya M, Rocca JP, Contreras-Saldivar A, Schwartz ME, Florman SS. J Hepatol. 2013 Feb 16. pii: S0168-8278(13)00121-9. doi: 10.1016/j.jhep.2013.02.003. [Epub ahead of print]


  68. Early Predictor of Mortality due to Irreversible Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma
    Kim SH, Kang DR, Lee JG, Kim DY, Ahn SH, Han KH, Chon CY, Kim KS. World J Surg. 2013 Feb 20. [Epub ahead of print]


  69. Completeness of reporting of chronic hepatitis B and C virus infections - michigan, 1995-2008
    Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2013 Feb 15;62:99-102.


  70. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients
    Wang HM, Hung CH, Lu SN, Chen CH, Lee CM, Hu TH, Wang JH. Liver Int. 2013 Jan 25. doi: 10.1111/liv.12118. [Epub ahead of print]


  71. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma
    Rimassa L, Personeni N, Simonelli M, Santoro A. Future Oncol. 2013 Feb;9(2):153-65. doi: 10.2217/fon.12.188.


  72. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies
    Lauer GM. J Infect Dis. 2013 Mar;207 Suppl 1:S7-S12. doi: 10.1093/infdis/jis762.


  73. Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments
    Wang PM, Hsu WC, Chung NN, Chang FL, Fogliata A, Cozzi L. Strahlenther Onkol. 2013 Apr;189(4):301-307. Epub 2013 Feb 20.


  74. Alpha-fetoprotein: A controversial prognostic biomarker for small hepatocellular carcinoma
    Asrih M, Lenglet S, Mach F, Montecucco F. World J Gastroenterol. 2013 Jan 21;19(3):328-30. doi: 10.3748/wjg.v19.i3.328.


  75. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP
    Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ. World J Gastroenterol. 2013 Jan 21;19(3):339-46. doi: 10.3748/wjg.v19.i3.339.


  76. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: A literature review
    Su JS, Chen YT, Wang RC, Wu CY, Lee SW, Lee TY. World J Gastroenterol. 2013 Jan 21;19(3):321-7. doi: 10.3748/wjg.v19.i3.321.


  77. Donor safety in live-related liver transplantation
    Wakade VA, Mathur SK. Indian J Surg. 2012 Feb;74(1):118-26. doi: 10.1007/s12262-011-0385-4. Epub 2011 Dec 29.


  78. Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated with Progression of Hepatocellular Carcinoma and Patient Outcomes
    Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, Karoly E, Qin LX, Ye QH, Jia HL, Fan J, Sun HC, Tang ZY, Wang XW. Gastroenterology. 2013 Jan 31. pii: S0016-5085(13)00150-9. doi: 10.1053/j.gastro.2013.01.054. [Epub ahead of print]


  79. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma
    Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Saeki C, Tajiri H. BMC Cancer. 2013 Feb 2;13:52. doi: 10.1186/1471-2407-13-52.


  80. Curative treatment for recurrent tumour implantation after ruptured hepatocellular carcinoma
    Chow KC, Tang CN, Lai ECh, Li MK. Hong Kong Med J. 2013 Feb;19(1):82-4. Hong Kong Med J. 2013 Feb;19(1):82-4.


  81. Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: A multicenter, exploratory analysis
    Silva MF, Sapisochin G, Strasser SI, Hewa-Geeganage S, Chen J, Wigg AJ, Jones R, Saraiva R, Kikuchi L, Carrilho F, Fontes PR, Charco R. Eur J Surg Oncol. 2013 Jan 30. pii: S0748-7983(12)01350-9. doi: 10.1016/j.ejso.2012.12.011. [Epub ahead of print]


  82. Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma
    Tohme S, Geller DA, Cardinal JS, Chen HW, Packiam V, Reddy S, Steel J, Marsh JW, Tsung A. HPB (Oxford). 2013 Mar;15(3):210-7. doi: 10.1111/j.1477-2574.2012.00541.x. Epub2012 Aug 12.


  83. Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection
    Chen X, Zhang B, Yin X, Ren Z, Qiu S, Zhou J. J Cancer Res Clin Oncol. 2013 Feb 3. [Epub ahead of print]


  84. Best radiological response to trans-arterial chemoembolization for hepatocellular carcinoma does not imply better outcomes
    Henry JC, Malhotra L, Khabiri H, Guy G, Michaels A, Hanje J, Azevedo M, Bloomston M, Schmidt CR. HPB (Oxford). 2013 Mar;15(3):196-202. doi: 10.1111/j.1477-2574.2012.00529.x. Epub 2012 Aug 28.


  85. Transplantation for hepatocellular carcinoma in younger patients has an equivocal survival advantage as compared with resection
    Graham JA, Newman DA, Smirniotopolous J, Shetty K, Slidell MB, Johnson LB. Transplant Proc. 2013 Jan;45(1):265-71. doi: 10.1016/j.transproceed.2012.07.151.


  86. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation
    Kim PT, Onaca N, Chinnakotla S, Davis GL, Jennings LW, McKenna GJ, Ruiz RM, Levy MF, Goldstein R, Klintmalm GB. Clin Transplant. 2013 Jan 28. doi: 10.1111/ctr.12089. [Epub ahead of print]


  87. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?
    Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA, Schaalan MF. J Immunotoxicol. 2013 Jan 25. [Epub ahead of print]CLD_HCC_Jun02252013-144138|Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma~Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. World J Gastroenterol. 2013 Jan 14;19(2):284-9. doi: 10.3748/wjg.v19.i2.284.


  88. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study
    Loomba R, Yang HI, Su J, Brenner D, Barrett-Connor E, Iloeje U, Chen CJ. Am J Epidemiol. 2013 Feb 15;177(4):333-42. doi: 10.1093/aje/kws252. Epub 2013 Jan 24.


  89. Factors related to postoperative pain among patients who underwent radiofrequency ablation of hepatocellular carcinoma
    Hsieh YC, Yap YS, Hung CH, Chen CH, Lu SN, Wang JH. Clin Radiol. 2013 Jan 23. pii: S0009-9260(13)00011-1. doi: 10.1016/j.crad.2012.12.006. [Epub ahead of print]


  90. Evaluation of the effect of sorafenib using serum NX-des-?-carboxyprothrombin in patients with hepatocellular carcinoma
    Miyahara K, Nouso K, Morimoto Y, Tomoda T, Kobayashi S, Takeuchi Y, Hagihara H, Kuwaki K, Ohnishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K; Okayama Liver Cancer Group. Hepatol Res. 2012 Dec 26. doi: 10.1111/hepr.12055. [Epub ahead of print]


  91. Extended Postinterventional Tumor Necrosis-Implication for Outcome in Liver Transplant Patients with Advanced HCC
    Kornberg A, Witt U, Matevossian E, Küpper B, Aßfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H. PLoS One. 2013;8(1):e53960. doi: 10.1371/journal.pone.0053960. Epub 2013 Jan 22.


  92. Expression of alpha 1,6-fucosyltransferase 8 in hepatitis B virus-related hepatocellular carcinoma influences tumour progression
    Ji J, Gu X, Fang M, Zhao Y, Yi C, Wang A, Gao C. Dig Liver Dis. 2013 Jan 23. pii: S1590-8658(12)00467-7. doi: 10.1016/j.dld.2012.12.007. [Epub ahead of print]


  93. Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma
    Kim YI, Park HC, Lim do H, Park HJ, Kang SW, Park SY, Kim JS, Han Y, Paik SW. Radiat Oncol J. 2012 Dec;30(4):189-96. doi: 10.3857/roj.2012.30.4.189. Epub 2012 Dec 31.


  94. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
    Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik S, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Liver Int. 2012 Nov 24. doi: 10.1111/liv.12083. [Epub ahead of print]


  95. Infection with Hepatitis C Virus is an Adverse Prognostic Factor after Liver Resection for Early-stage Hepatocellular Carcinoma : Implications for the Management of Hepatocellular Carcinoma Eligible for Liver Transplantation
    Chirica M, Tranchart H, Tan V, Faron M, Balladur P, Paye F. Ann Surg Oncol. 2013 Jan 23. [Epub ahead of print]


  96. Factors Associated with Outcomes and Response to Therapy in Patients with Infiltrative Hepatocellular Carcinoma
    Mehta N, Fidelman N, Sarkar M, Yao FY. Clin Gastroenterol Hepatol. 2013 Jan 17. pii: S1542-3565(13)00088-8. doi: 10.1016/j.cgh.2012.12.030. [Epub ahead of print]


  97. Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma
    Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon AH. World J Surg. 2013 Jan 24. [Epub ahead of print]


  98. Surgical Resection in Hepatocellular Carcinoma Patients with Minimal Background Fibrosis: A Strategy in the Era of Organ Shortage
    Groeschl RT, Clark Gamblin T, Turaga KK. Ann Surg Oncol. 2013 Jan 20. [Epub ahead of print]


  99. Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression
    Koda M, Tokunaga S, Miyoshi K, Kishina M, Fujise Y, Kato J, Matono T, Murawaki Y, Kakite S, Yamashita E. J Gastroenterol. 2013 Jan 22. [Epub ahead of print]


  100. Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan
    Wu WC, Chen YT, Hwang CY, Su1 CW, Li SY, Chen TJ, Liu CJ, Kao WY, Chao Y, Lin HC, Wu JC. Liver Int. 2012 Dec 21. doi: 10.1111/liv.12103. [Epub ahead of print]


  101. Statins in nonalcoholic Fatty liver disease and steatohepatitis: updated review
    Nseir W, Mahamid M. Curr Atheroscler Rep. 2013 Mar;15(3):305. doi: 10.1007/s11883-012-0305-5.


  102. The "stone-like" pattern of LC3A expression and its clinicopathologic significance in hepatocellular carcinoma
    Xi SY, Lu JB, Chen JW, Cao Y, Luo RZ, Wu QL, Cai MY. Biochem Biophys Res Commun. 2013 Jan 16. pii: S0006-291X(13)00096-X. doi: 10.1016/j.bbrc.2012.12.151. [Epub ahead of print]


  103. Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months: A 15-Year Prospective Study
    Han KH, Kim DY, Park JY, Ahn SH, Kim J, Kim SU, Kim JK, Lee KS, Chon CY. J Clin Gastroenterol. 2013 Jan 18. [Epub ahead of print]


  104. Alpha-Fetoprotein: The Predictor of Microvascular Invasion in Solitary Small Hepatocellular Carcinoma and Criterion for Anatomic or Non-Anatomic Hepatic Resection
    Fan LF, Zhao WC, Yang N, Yang GS. Hepatogastroenterology. 2013 Jan 16;60(126). doi: 10.5754/hge121039. [Epub ahead of print]


  105. The ART of decision making: Retreatment with TACE in patients with hepatocellular carcinoma
    Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M. Hepatology. 2013 Jan 12. doi: 10.1002/hep.26256. [Epub ahead of print]


  106. Plasma CD24 as a Novel Useful Biomarker in Differentiating Hepatocellular Carcinoma Patients from Normal Individuals
    Liu B, Yang Y, Han S, Zhang L, Bai Y, Fang X. Hepatogastroenterology. 2013 Jan 16;60(126). doi: 10.5754/hge121043. [Epub ahead of print]


  107. Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma
    Connolly GC, Safadjou S, Kashyap R, Chen R, Orloff MS, Hezel AF. BMC Gastroenterol. 2013 Jan 14;13:9. doi: 10.1186/1471-230X-13-9.


  108. Influence of human MIF promoter polymorphism on hepatocellular carcinoma prognosis
    Yuan T, Tang C, Chen M, Deng S, Chen P. Genet Mol Res. 2013 Jan 4;12(AOP). [Epub ahead of print]


  109. PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma
    Kimura O, Kondo Y, Shimosegawa T. PPAR Res. 2012;2012:574180. doi: 10.1155/2012/574180. Epub 2012 Dec 16.


  110. Propofol induces apoptosis of hepatocellular carcinoma cells by upregulation of microRNA-199a expression
    Zhang J, Wu GQ, Zhang Y, Feng ZY, Zhu SM. Cell Biol Int. 2012 Dec 27:1-6. doi: 10.1002/cbin.10034. [Epub ahead of print]


  111. Hepatocellular Carcinoma Surveillance at 4- vs. 12-Month Intervals for Patients With Chronic Viral Hepatitis: A Randomized Study in Community
    Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, Lu SN. Am J Gastroenterol. 2013 Jan 15. doi: 10.1038/ajg.2012.445. [Epub ahead of print]


  112. Role of branched chain amino acids in cerebral ammonia homeostasis related to hepatic encephalopathy
    Bak LK, Waagepetersen HS, Sørensen M, Ott P, Vilstrup H, Keiding S, Schousboe A. Metab Brain Dis. 2013 Jan 31. [Epub ahead of print]


  113. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma
    Di Costanzo GG, Tortora R, De Luca M, Galeota Lanza A, Lampasi F, Tartaglione MT, Picciotto FP, Imparato M, Mattera S, Cordone G, Ascione A. Med Oncol. 2013 Mar;30(1):446. doi: 10.1007/s12032-012-0446-y. Epub 2013 Jan 10.


  114. Performance Status Enhances the Selection of Treatment for Patients with Hepatocellular Carcinoma Within the Milan Criteria
    Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Lee FY, Huo TI. Ann Surg Oncol. 2013 Jan 11. [Epub ahead of print]


  115. Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
    Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Gastroenterology. 2013 Jan 9. pii: S0016-5085(13)00005-X. doi: 10.1053/j.gastro.2013.01.002. [Epub ahead of print]


  116. Optimal Measurement Modality and Method for Evaluation of Responses to Transarterial Chemoembolization of Hepatocellular Carcinoma Based on Enhancement Criteria
    Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC. J Vasc Interv Radiol. 2013 Jan 8. pii: S1051-0443(12)01130-X. doi: 10.1016/j.jvir.2012.10.022. [Epub ahead of print]


  117. Enhanced production of CTGF and IL-11 from highly metastatic hepatoma cells under hypoxic conditions: an implication of hepatocellular carcinoma metastasis to bone
    Gao YB, Xiang ZL, Zhou LY, Wu ZF, Fan J, Zeng HY, Zeng ZC. J Cancer Res Clin Oncol. 2013 Jan 10. [Epub ahead of print]


  118. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes
    Doycheva I, Patel N, Peterson M, Loomba R. J Diabetes Complications. 2013 Jan 8. pii: S1056-8727(12)00298-X. doi: 10.1016/j.jdiacomp.2012.10.008. [Epub ahead of print]


  119. Alcohol consumption, folate intake, hepatocellular carcinoma incidence and liver disease mortality
    Persson EC, Schwartz LM, Park Y, Trabert B, Hollenbeck AR, Graubard BI, Freedman ND, McGlynn KA. Cancer Epidemiol Biomarkers Prev. 2013 Jan 10. [Epub ahead of print]


  120. Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma
    Ishibashi M, Kogo R, Shibata K, Sawada G, Takahashi Y, Kurashige J, Akiyoshi S, Sasaki S, Iwaya T, Sudo T, Sugimachi K, Mimori K, Wakabayashi G, Mori M. Oncol Rep. 2012 Dec 28. doi: 10.3892/or.2012.2219. [Epub ahead of print]


  121. The homeobox transcription factor Prox1 inhibits proliferation of hepatocellular carcinoma cells by inducing p53-dependent senescence-like phenotype
    Chang TM, Hung WC. Cancer Biol Ther. 2013 Jan 4;14(3). [Epub ahead of print]


  122. New progress of non-surgical treatments for hepatocellular carcinoma
    Cheng JW, Lv Y. Med Oncol. 2013 Mar;30(1):381. doi: 10.1007/s12032-012-0381-y. Epub 2013 Jan 6.


  123. High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques
    Qin X, Chen Q, Sun C, Wang C, Peng Q, Xie L, Liu Y, Li S. Med Oncol. 2013 Mar;30(1):420. doi: 10.1007/s12032-012-0420-8. Epub 2013 Jan 6.


  124. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis
    Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. J Cancer Res Clin Oncol. 2013 Jan 5. [Epub ahead of print]


  125. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma
    Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY. Nat Med. 2013 Jan 6. doi: 10.1038/nm.3043. [Epub ahead of print]


  126. Effects of common polymorphisms rs2910164 in miR-146a and rs3746444 in miR-499 on cancer susceptibility: a meta-analysis
    Yin Z, Yan L, Cui Z, Li X, Ren Y, Zhou B. Mol Biol Rep. 2013 Jan 6. [Epub ahead of print]


  127. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma
    Gu H, Guo X, Zou L, Zhu H, Zhang J. Mol Cell Biochem. 2013 Jan 6. [Epub ahead of print]


  128. Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma
    Lu JW, Lin YM, Chang JG, Yeh KT, Chen RM, Tsai JJ, Su WW, Hu RM. Med Oncol. 2013 Mar;30(1):379. doi: 10.1007/s12032-012-0379-5. Epub 2013 Jan 5.


  129. Thrombocytosis and Hepatocellular Carcinoma
    Carr BI, Guerra V. Dig Dis Sci. 2013 Jan 12. [Epub ahead of print]


  130. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization
    Jang ES, Yoon JH, Chung JW, Cho EJ, Yu SJ, Lee JH, Kim YJ, Lee HS, Kim CY. J Cancer Res Clin Oncol. 2013 Jan 3. [Epub ahead of print]


  131. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3?cm or less
    Imai K, Beppu T, Chikamoto A, Doi K, Okabe H, Hayashi H, Nitta H, Ishiko T, Takamori H, Baba H. Hepatol Res. 2012 Dec 4. doi: 10.1111/hepr.12035. [Epub ahead of print]


  132. Impact of genetic targets on cancer therapy: hepatocellular cancer
    Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O'Carroll K. Adv Exp Med Biol. 2013;779:67-90. doi: 10.1007/978-1-4614-6176-0_4.


  133. Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials
    Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. PLoS One. 2012;7(12):e49717. doi: 10.1371/journal.pone.0049717. Epub 2012 Dec 19.


  134. Doxorubicin-Eluting Bead versus Conventional TACE for Unresectable Hepatocellular Carcinoma: A Meta-Analysis
    Gao S, Yang Z, Zheng Z, Yao J, Deng4 M, Xie H, Zheng S, Zhou L. Hepatogastroenterology. 2013 Jan 3;60(126). doi: 10.5754/hge121025. [Epub ahead of print]


  135. Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide
    Palliyaguru DL, Wu F. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013 Jan 2. [Epub ahead of print]


  136. Prognostic value of ?-fetoprotein and des-?-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization
    Lee YK, Kim SU, Kim do Y, Ahn SH, Lee KH, Lee do Y, Han KH, Chon CY, Park JY. BMC Cancer. 2013 Jan 3;13:5. doi: 10.1186/1471-2407-13-5.


  137. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
    Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Chang LJ, Liu C, Nelson DR. Cancer Immunol Immunother. 2012 Dec 7. [Epub ahead of print]


  138. Hepatocellular Carcinoma Radiation Therapy: Review of Evidence and Future Opportunities
    Klein J, Dawson LA. Int J Radiat Oncol Biol Phys. 2012 Dec 6. pii: S0360-3016(12)03510-9. doi: 10.1016/j.ijrobp.2012.08.043. [Epub ahead of print]


  139. Radiofrequency ablation versus hepatic resection for hepatocellular carcinoma within the Milan criteria - A comparative study
    Lai EC, Tang CN. Int J Surg. 2012 Dec 6. pii: S1743-9191(12)00842-4. doi: 10.1016/j.ijsu.2012.11.019. [Epub ahead of print]


  140. Overexpression of MMSET is Correlation with Poor Prognosis in Hepatocellular Carcinoma
    Zhou P, Wu LL, Wu KM, Jiang W, Li JD, Zhou LD, Li XY, Chang S, Huang Y, Tan H, Zhang GW, He F, Wang ZM. Pathol Oncol Res. 2012 Dec 8. [Epub ahead of print]


  141. Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization
    Kim BK, Kim SU, Kim MJ, Kim KA, Kim DY, Park JY, Ahn SH, Han KH, Chon CY. Clin Cancer Res. 2012 Dec 7. [Epub ahead of print]


  142. Could radiofrequency ablation replace liver resection for small hepatocellular carcinoma in patients with compensated cirrhosis? A 5-year follow-up
    Desiderio J, Trastulli S, Pasquale R, Cavaliere D, Cirocchi R, Boselli C, Noya G, Parisi A. Langenbecks Arch Surg. 2013 Jan;398(1):55-62. doi: 10.1007/s00423-012-1029-2. Epub 2012 Dec 7.


  143. Milan Criteria, Multi-nodularity, and Microvascular Invasion Predict the Recurrence Patterns of Hepatocellular Carcinoma After Resection
    Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. J Gastrointest Surg. 2012 Dec 6. [Epub ahead of print]


  144. Pretransplantation ?-Fetoprotein Slope and Milan Criteria: Strong Predictors of Hepatocellular Carcinoma Recurrence After Transplantation
    Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, Deschênes M, Paraskevas S, Hassanain M, Tchervenkov JI. Transplantation. 2013 Jan 15;95(1):228-33. doi: 10.1097/TP.0b013e31827743d7.


  145. Quantitative therapy response assessment by volumetric iodine-uptake measurement: Initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib
    Dai X, Schlemmer HP, Schmidt B, Höh K, Xu K, Ganten TM, Ganten MK. Eur J Radiol. 2013 Feb;82(2):327-34. doi: 10.1016/j.ejrad.2012.11.013. Epub 2012 Dec 12.


  146. Donor-Transmitted Malignancy in a Liver Transplant Recipient: A Case Report and Review of Literature
    Kim B, Woreta T, Chen PH, Limketkai B, Singer A, Dagher N, Cameron A, Lin MT, Kamel I, Gurakar A. Dig Dis Sci. 2012 Dec 16. [Epub ahead of print]


  147. Improving Screening for Hepatocellular Carcinoma by Incorporating Data on Levels of ?-Fetoprotein, Over Time
    Lee E, Edward S, Singal AG, Lavieri MS, Volk M. Clin Gastroenterol Hepatol. 2012 Dec 12. pii: S1542-3565(12)01430-9. doi: 10.1016/j.cgh.2012.11.029. [Epub ahead of print]


  148. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma
    Xiong JJ, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G, Sutton R, Liu XB, Hu WM. World J Gastroenterol. 2012 Dec 7;18(45):6657-68. doi: 10.3748/wjg.v18.i45.6657.


  149. Puncture injection of para-toluenesulfonamide combined with chemoembolization for advanced hepatocellular carcinoma
    He Q, Kuang AR, Guan YS, Liu YQ. World J Gastroenterol. 2012 Dec 14;18(46):6861-4. doi: 10.3748/wjg.v18.i46.6861.


  150. The economic burden of advanced liver disease among patients with Hepatitis C Virus: a large state Medicaid perspective
    Menzin J, White LA, Nichols C, Deniz B BMC Health Serv Res. 2012 Dec 15;12:459. doi: 10.1186/1472-6963-12-459.


  151. Tumour seeding after percutaneous cryoablation for hepatocellular carcinoma
    Wang CP, Wang H, Qu JH, Lu YY, Bai WL, Dong Z, Gao XD, Rong GH, Zeng Z, Yang YP. World J Gastroenterol. 2012 Dec 7;18(45):6587-96. doi: 10.3748/wjg.v18.i45.6587.


  152. Performance of Imaging Modalities in the Diagnosis of Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis
    Floriani I, D'Onofrio M, Rulli E, Chen MH, Li R, Musicco L. Ultraschall Med. 2012 Dec 13. [Epub ahead of print]


  153. Long-term effectiveness of Radiofrequency Ablation for solitary small Hepatocellular Carcinoma: A retrospective analysis of 363 patients
    Francica G, Saviano A, De Sio I, De Matthaeis N, Brunello F, Cantamessa A, Giorgio A, Scognamiglio U, Fornari F, Giangregorio F, Piscaglia F, Gualandi S, Caturelli E, Roselli P, Rapaccini GL, Pompili M. Dig Liver Dis. 2012 Dec 12. pii: S1590-8658(12)00425-2. doi: 10.1016/j.dld.2012.10.022. [Epub ahead of print]


  154. Hepatic resection in hepatocarcinoma: A comparative study between patients under and over 70 years-old
    [Article in English, Spanish] Murillo A, Artigas V, González JA, Gallego A, Montserrat E, Rodriguez M, Trías M. Cir Esp. 2012 Dec 12. pii: S0009-739X(12)00282-5. doi: 10.1016/j.ciresp.2012.07.016. [Epub ahead of print]


  155. Analysis of Notch and TGF-? Signaling Expression in Different Stages of Disease Progression During Hepatitis B Virus Infection
    Trehanpati N, Shrivastav S, Shivakumar B, Khosla R, Bhardwaj S, Chaturvedi J, Sukriti, Kumar B, Bose S, Mani Tripathi D, Das T, Sakhuja P, Rastogi A, Bhihari C, Singh S, Gupta S, Kottilil S, Sarin SK. Clin Transl Gastroenterol. 2012 Oct 4;3:e23. doi: 10.1038/ctg.2012.17.


  156. The accuracy of noninvasive methods in the prediction of clinically relevant outcomes in patients with chronic liver disease
    Fraquelli M, Pozzi R. Expert Rev Gastroenterol Hepatol. 2012 Dec;6(6):679-82. doi: 10.1586/egh.12.55.


  157. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation
    Zeng Z, Ren J, O Neil M, Zhao J, Bridges B, Cox J, Abdulkarim B, Schmitt TM, Kumer SC, Weinman SA. BMC Cancer. 2012 Dec 7;12(1):584. [Epub ahead of print]


  158. Large primary hepatocellular carcinoma:TACE monotherapy versus combined TACE-PMCT
    Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, Zhou JX, Hu RM, Tan QY. J Gastroenterol Hepatol. 2012 Dec 7. doi: 10.1111/jgh.12088. [Epub ahead of print]


  159. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma
    Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. J Gastroenterol Hepatol. 2012 Dec 7. doi: 10.1111/jgh.12087. [Epub ahead of print]


  160. Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma
    Shindoh J, Hasegawa K, Inoue Y, Ishizawa T, Nagata R, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. HPB (Oxford). 2013 Jan;15(1):31-9. doi: 10.1111/j.1477-2574.2012.00552.x. Epub 2012 Aug 26.


  161. Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review
    Rubin J, Ayoub N, Kaldas F, Saab S. Exp Clin Transplant. 2012 Dec;10(6):531-43.


  162. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C
    Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Dig Liver Dis. 2012 Dec 5. pii: S1590-8658(12)00417-3. doi: 10.1016/j.dld.2012.10.019. [Epub ahead of print]


  163. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication?
    Santambrogio R, Kluger MD, Costa M, Belli A, Barabino M, Laurent A, Opocher E, Azoulay D, Cherqui D. HPB (Oxford). 2013 Jan;15(1):78-84. doi: 10.1111/j.1477-2574.2012.00594.x. Epub 2012 Oct 24.


  164. N-WASP is highly expressed in hepatocellular carcinoma and associated with poor prognosis
    Jin KM, Lu M, Liu FF, Gu J, Du XJ, Xing BC. Surgery. 2012 Dec 4. pii: S0039-6060(12)00546-6. doi: 10.1016/j.surg.2012.08.067. [Epub ahead of print]


  165. Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma
    Zhang T, Cai J, Chang J, Yu D, Wu C, Yan T, Zhai K, Bi X, Zhao H, Xu J, Tan W, Qu C, Lin D. Hum Mol Genet. 2012 Dec 18. [Epub ahead of print]


  166. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?
    Fujiki M, Aucejo F, Kim R. Clin Transplant. 2012 Dec 6. doi: 10.1111/ctr.12042. [Epub ahead of print]


  167. Local access to subspecialty care influences the chance of receiving a liver transplant
    Barritt AS 4th, Telloni SA, Potter CW, Gerber DA, Hayashi PH. Liver Transpl. 2012 Dec 5. doi: 10.1002/lt.23588. [Epub ahead of print]


  168. Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
    Lu LC, Shao YY, Kuo RN, Lin ZZ, Yeh YC, Shau WY, Hsu CH, Cheng AL, Lai MS. Cancer. 2012 Dec 4. doi: 10.1002/cncr.27800. [Epub ahead of print]


  169. Percutaneous Radiofrequency Ablation Versus Partial Hepatectomy for Small Centrally Located Hepatocellular Carcinoma
    Guo WX, Sun JX, Cheng YQ, Shi J, Li N, Xue J, Wu MC, Chen Y, Cheng SQ. World J Surg. 2012 Dec 5. [Epub ahead of print]


  170. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
    Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX. Exp Hematol Oncol. 2012 Apr 26;1(1):11. doi: 10.1186/2162-3619-1-11.


  171. Principles, effectiveness and caveats in screening for cancer
    Bretthauer M, Kalager M. Br J Surg. 2013 Jan;100(1):55-65. doi: 10.1002/bjs.8995.


  172. Multimodality Treatment for Early-Stage Hepatocellular Carcinoma: A Bridging Therapy for Liver Transplantation
    Ashoori N, Bamberg F, Paprottka P, Rentsch M, Kolligs FT, Siegert S, Peporte A, Al-Tubaikh JA, D'Anastasi M, Hoffmann RT, Reiser MF, Jakobs TF. Digestion. 2012 Nov 28;86(4):338-348. [Epub ahead of print]


  173. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: A pilot study
    Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, Sumino Y. World J Gastroenterol. 2012 Oct 28;18(40):5753-8. doi: 10.3748/wjg.v18.i40.5753.


  174. Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma
    Nishikawa H, Osaki Y, Iguchi E, Takeda H, Ohara Y, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Anticancer Res. 2012 Nov;32(11):5059-65.


  175. Recent advances in radiofrequency ablation for the management of hepatocellular carcinoma
    Himoto T, Kurokohchi K, Watanabe S, Masaki T. Hepat Mon. 2012 Oct;12(10 HCC):e5945. doi: 10.5812/hepatmon.5945. Epub 2012 Oct 10.


  176. Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients
    Chen TM, Chang CC, Huang PT, Wen CF, Lin CC. Aliment Pharmacol Ther. 2012 Nov 22. doi: 10.1111/apt.12144. [Epub ahead of print]


  177. Allografts Positive for Hepatitis B Surface Antigen in Liver Transplant for Disease Related to Hepatitis B Virus
    Ju W, Chen M, Guo Z, Wang D, Zhu X, Huang J, He X. Exp Clin Transplant. 2012 Nov 20. doi: 10.6002/ect.2012.0095. [Epub ahead of print]


  178. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis
    Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Clin Transplant. 2012 Nov 15. doi: 10.1111/ctr.12031. [Epub ahead of print]


  179. Living-Donor Liver Transplant With an Interposition Graft of the Inferior Vena Cava for Hepatocellular Carcinoma: Beyond the Milan Criteria and Within the UCSF Criteria
    Ahn KS, Kang KJ, Kim HT, Kim YH, Park UJ, Lim TJ, Park TJ, Cho WH. Exp Clin Transplant. 2012 Nov 19. doi: 10.6002/ect.2012.0133. [Epub ahead of print]


  180. An overview of biomarkers for the diagnosis of hepatocellular carcinoma
    Abu El Makarem M. Hepat Mon. 2012 Oct;12(10 HCC):e6122. Epub 2012 Oct 20.


  181. The role of aflatoxins in hepatocellular carcinoma.
    Wu HC, Santella R. Hepat Mon. 2012 Oct;12(10 HCC):e7238. doi: 10.5812/hepatmon.7238. Epub 2012 Oct 11.


  182. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma
    Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Exp Ther Med. 2012 Aug;4(2):188-196. Epub 2012 May 10.


  183. Interim analysis of start: Study in asia of the combination of TACE (Transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial
    Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY, Chao Y. Int J Cancer. 2012 Nov 6. doi: 10.1002/ijc.27925. [Epub ahead of print]


  184. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials
    Lu Z, Wen F, Guo Q, Liang H, Mao X, Sun H. Eur J Gastroenterol Hepatol. 2012 Nov 5. [Epub ahead of print]


  185. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma
    Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura S, Kasai C, Kusagawa S, Yoneda M, Yamamoto N, Takei Y, Nobori T, Ito M. Int J Oncol. 2012 Oct 24. doi: 10.3892/ijo.2012.1676. [Epub ahead of print]


  186. Low Hepatitis C Viral Load Predicts Better Long-Term Outcomes in Patients Undergoing Resection of Hepatocellular Carcinoma Irrespective of Serologic Eradication of Hepatitis C Virus
    Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. J Clin Oncol. 2012 Nov 5. [Epub ahead of print]


  187. Tackling hepatitis B virus-associated hepatocellular carcinoma-the future is now
    Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Cancer Metastasis Rev. 2012 Nov 1. [Epub ahead of print]


  188. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis
    Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Scand J Gastroenterol. 2012 Nov 9. [Epub ahead of print]


  189. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma
    Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, Chang JY, Whang-Peng J, Lin PW, Huang JD, Chen LT. Aliment Pharmacol Ther. 2012 Nov 8. doi: 10.1111/apt.12132. [Epub ahead of print]


  190. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Cancer. 2012 Nov 6. doi: 10.1002/cncr.27859. [Epub ahead of print]


  191. HCC, diet and metabolic factors: Diet and HCC
    Montella M, Crispo A, Giudice A. Hepat Mon. 2011 Mar;11(3):159-62.


  192. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C
    Morgan TR. Recent Results Cancer Res. 2011;188:85-99.


  193. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study
    Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Cancer Causes Control. 2011 Mar;22(3):503-10. Epub 2011 Jan 22.


  194. Detection of TFPI2 Methylation in the Serum of Hepatocellular Carcinoma Patients
    Sun FK, Fan YC, Zhao J, Zhang F, Gao S, Zhao ZH, Sun Q, Wang K. Dig Dis Sci. 2012 Oct 31. [Epub ahead of print]


  195. Quality Improvement Measures Lead to Higher Surveillance Rates for Hepatocellular Carcinoma in Patients with Cirrhosis
    Aberra FB, Essenmacher M, Fisher N, Volk ML. Dig Dis Sci. 2012 Nov 1. [Epub ahead of print]


  196. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients
    Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B, Yang H. PLoS One. 2012;7(10):e47687. doi: 10.1371/journal.pone.0047687. Epub 2012 Oct 24.


  197. OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma
    Zhao X, Tian C, Puszyk WM, Ogunwobi OO, Cao M, Wang T, Cabrera R, Nelson DR, Liu C. Lab Invest. 2012 Oct 29. doi: 10.1038/labinvest.2012.144. [Epub ahead of print]


  198. Radiotherapy and hepatocellular carcinoma: update and review of the literature
    Ursino S, Greco C, Cartei F, Colosimo C, Stefanelli A, Cacopardo B, Berretta M, Fiorica F. Eur Rev Med Pharmacol Sci. 2012 Nov;16(11):1599-604.


  199. Hemorrhagic events in hepatocellular carcinoma patients treated with anti-angiogenic therapies
    Duffy A, Wilkerson J, Greten TF. Hepatology. 2012 Oct 30. doi: 10.1002/hep.26120. [Epub ahead of print]


  200. TGF-? Signaling in Onset and Progression of Hepatocellular Carcinoma
    Meindl-Beinker NM, Matsuzaki K, Dooley S. Dig Dis. 2012;30(5):514-23. doi: 10.1159/000341704. Epub 2012 Oct 24.


  201. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma
    Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S, Tonini G. Expert Rev Anticancer Ther. 2012 Oct 24. [Epub ahead of print]


  202. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma
    Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, Clark V, Morelli G, Firpi R, Nelson DR. Aliment Pharmacol Ther. 2012 Oct 24. doi: 10.1111/apt.12098. [Epub ahead of print]


  203. Short- and Long-term Outcomes after Laparoscopic and Open Hepatectomy for Hepatocellular Carcinoma: A Global Systematic Review and Meta-analysis
    Yin Z, Fan X, Ye H, Yin D, Wang J. Ann Surg Oncol. 2012 Oct 26. [Epub ahead of print]


  204. Resection or Transplantation for Early Hepatocellular Carcinoma in a Cirrhotic Liver: Does Size Define the Best Oncological Strategy?
    Adam R, Bhangui P, Vibert E, Azoulay D, Pelletier G, Duclos-Vallée JC, Samuel D, Guettier C, Castaing D. Ann Surg. 2012 Oct 26. [Epub ahead of print]


  205. Clinical spectrum and therapy of non-alcoholic steatohepatitis
    Day CP. Dig Dis. 2012;30 Suppl 1:69-73. doi: 10.1159/000341128. Epub 2012 Oct 11.


  206. Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naïve adult patients with chronic hepatitis B
    Zhang TT, Ye J, Xia SL, Zhang YF, Su Q, Zhang ZH, Li X. Infection. 2012 Oct 30. [Epub ahead of print]


  207. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NALFD)
    Podrini C, Borghesan M, Greco A, Pazienza V, Mazzoccoli G, Vinciguerra M. Curr Pharm Des. 2012 Oct 18. [Epub ahead of print]


  208. Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma
    Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, Festi D, Pinna AD. Ann Surg. 2012 Nov;256(5):706-13. doi: 10.1097/SLA.0b013e3182724ce8.


  209. Carbon Dioxide (CO2) Ablation as a Remedy for Hepatocellular Carcinoma
    Liang DY, Zhou SC, Zhou H, Tong M. Hepatogastroenterology. 2012 Oct 29;60(122). doi: 10.5754/hge12734. [Epub ahead of print]


  210. Efficacy of Chemoembolization for Recurrent HCC after Curative Ablation Therapy
    Okabe N, Morimoto M, Kondo M, Moriya S, Numata K, Maeda S, Tanaka K. Hepatogastroenterology. 2012 Oct 29;60(123). doi: 10.5754/hge12767. [Epub ahead of print]


  211. Liver cancer and alcohol
    Grewal P, Viswanathen VA. Clin Liver Dis. 2012 Nov;16(4):839-50. doi: 10.1016/j.cld.2012.08.011.


  212. Half-Life of Serum Alpha-Fetoprotein: An Early Prognostic Index of Recurrence and Survival After Hepatic Resection for Hepatocellular Carcinoma
    Shim JH, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Ann Surg. 2012 Oct 26. [Epub ahead of print]


  213. Adipocytokines and hepatocellular carcinoma
    Wieser V, Moschen AR, Tilg H. Dig Dis. 2012;30(5):508-13. doi: 10.1159/000341702. Epub 2012 Oct 24.


  214. Nonalcoholic Fatty liver disease in lean individuals in the United States
    Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Medicine (Baltimore). 2012 Nov;91(6):319-27. doi: 10.1097/MD.0b013e3182779d49.


  215. Early diffuse recurrence of hepatocellular carcinoma after percutaneous radiofrequency ablation: analysis of risk factors
    Lee HY, Rhim H, Lee MW, Kim YS, Choi D, Park MJ, Kim YK, Kim SH, Lim HK. Eur Radiol. 2012 Oct 20. [Epub ahead of print]


  216. Expression of Serotonin Receptors in Human Hepatocellular Cancer
    Soll C, Riener MO, Oberkofler CE, Hellerbrand C, Wild PJ, Deoliveira ML, Clavien PA. Clin Cancer Res. 2012 Oct 19. [Epub ahead of print]


  217. Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma
    Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR. Cardiovasc Intervent Radiol. 2012 Oct 24. [Epub ahead of print]


  218. Emerging Leader Lecture Non-alcoholic fatty liver disease in Asia - A story of growth
    Wong VW. J Gastroenterol Hepatol. 2012 Oct 24. doi: 10.1111/jgh.12011. [Epub ahead of print]


  219. Risk stratification for hepatitis B virus related hepatocellular carcinoma
    Lin CL, Kao JH. J Gastroenterol Hepatol. 2012 Oct 24. doi: 10.1111/jgh.12010. [Epub ahead of print]


  220. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period
    Song do S, Bae SH. Clin Mol Hepatol. 2012 Sep;18(3):258-67. doi: 10.3350/cmh.2012.18.3.258. Epub 2012 Sep 25.


  221. Hepatocellular carcinoma in the elderly: clinical characteristics, treatment, survival analysis in korean patients older than 70 years
    Kim YJ, Jang BK, Kim ES, Chung WJ, Park KS, Cho KB, Hwang JS. J Korean Med Sci. 2012 Oct;27(10):1147-54. doi: 10.3346/jkms.2012.27.10.1147. Epub 2012 Oct 2.


  222. High-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients awaiting liver transplantation
    Cheung TT, Chok KSh, Lo RC, Sharr WW, Chan SC, Poon RT, Fan ST, Lo CM. Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):542-4.


  223. Marginal survival benefit in the treatment of early hepatocellular carcinoma
    Midorikawa Y, Takayama T, Shimada K, Nakayama H, Higaki T, Moriguchi M, Nara S, Tsuji S, Tanaka M. J Hepatol. 2012 Oct 9. pii: S0168-8278(12)00757-X. doi: 10.1016/j.jhep.2012.09.026. [Epub ahead of print]


  224. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review
    Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, Xu Y, Wang Z, Qiu SJ, Fan J, Zhou J. Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):458-66.


  225. Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma
    Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Oncology. 2012 Oct 13;84(1):6-13. [Epub ahead of print]


  226. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas
    Li S, Mao M. Cancer Lett. 2012 Oct 12. pii: S0304-3835(12)00591-5. doi: 10.1016/j.canlet.2012.09.027. [Epub ahead of print]


  227. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases
    Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L, Hawk E, Wu X. J Natl Cancer Inst. 2012 Oct 17;104(20):1599-611. doi: 10.1093/jnci/djs372.


  228. In Vivo Screening of Hepatocellular Carcinoma Using AC Susceptibility of Anti-Alpha Fetoprotein-Activated Magnetic Nanoparticles
    Chieh JJ, Huang KW, Lee YD, Horng HE, Yang HC, Hong CY. PLoS One. 2012;7(10):e46756. doi: 10.1371/journal.pone.0046756. Epub 2012 Oct 8.


  229. In Vivo Screening of Hepatocellular Carcinoma Using AC Susceptibility of Anti-Alpha Fetoprotein-Activated Magnetic Nanoparticles
    Chieh JJ, Huang KW, Lee YD, Horng HE, Yang HC, Hong CY. PLoS One. 2012;7(10):e46756. doi: 10.1371/journal.pone.0046756. Epub 2012 Oct 8.


  230. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma
    Maluccio M, Covey A. CA Cancer J Clin. 2012 Oct 15. doi: 10.3322/caac.21161. [Epub ahead of print]


  231. Diabetes Mellitus Is Associated With the Presence of Metastatic Spread at Disease Presentation in Hepatocellular Carcinoma
    Connolly GC, Safadjou S, Chen R, Nduaguba A, Dunne R, Khorana AA, Hezel AF. Cancer Invest. 2012 Oct 16. [Epub ahead of print]


  232. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes
    Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. J Gastroenterol. 2012 Oct 12. [Epub ahead of print]


  233. Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma
    Kim DW, Lee SA, Hwang ES, Kook YH, Kim BJ. PLoS One. 2012;7(10):e47372. doi: 10.1371/journal.pone.0047372. Epub 2012 Oct 10.


  234. Metabolic Disorders, Non-Alcoholic Fatty Liver Disease and Major Liver Resection: An Underestimated Perioperative Risk
    Zarzavadjian Le Bian A, Costi R, Constantinides V, Smadja C. J Gastrointest Surg. 2012 Oct 9. [Epub ahead of print]


  235. Pre-S Mutation Is a Significant Risk Factor for Hepatocellular Carcinoma Development: A Long-Term Retrospective Cohort Study
    Sinn DH, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Yoo BC. Dig Dis Sci. 2012 Sep 30. [Epub ahead of print]


  236. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature
    Sarpel U, Ayo D, Lobach I, Xu R, Newman E. HPB (Oxford). 2012 Nov;14(11):741-5. doi: 10.1111/j.1477-2574.2012.00507.x. Epub 2012 Jun 27.


  237. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature
    Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS. Eur J Gastroenterol Hepatol. 2012 Oct 5. [Epub ahead of print]


  238. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
    Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A. Ann Oncol. 2012 Oct 5. [Epub ahead of print]


  239. Hepatocellular carcinoma recurrence among liver transplant recipients within the milan criteria
    Felga G, Evangelista AS, Salvalaggio PR, Curvelo LA, Della Guardia B, Almeida MD, Afonso RC, Ferraz-Neto BH. Transplant Proc. 2012 Oct;44(8):2459-61. doi: 10.1016/j.transproceed.2012.07.004.


  240. Nonalcoholic Fatty Liver Disease and Hepatocellular Cancer: A Systematic Review
    White DL, Kanwal F, El-Serag HB. Clin Gastroenterol Hepatol. 2012 Oct 4. pii: S1542-3565(12)01153-6. doi: 10.1016/j.cgh.2012.10.001. [Epub ahead of print]


  241. Current status of multimodal & combination therapy for hepatocellular carcinoma
    Yang J, Yan L, Wang W. Indian J Med Res. 2012 Sep;136(3):391-403.


  242. Linear enhancement after radio-frequency ablation for hepatocellular carcinoma: is it a sign of recurrence?
    Takahashi M, Maruyama H, Shimada T, Kamezaki H, Okabe S, Kanai F, Yoshikawa M, Yokosuka O. Ultrasound Med Biol. 2012 Nov;38(11):1902-10. doi: 10.1016/j.ultrasmedbio.2012.07.003.


  243. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study
    Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V. World J Hepatol. 2012 Sep 27;4(9):256-61. doi: 10.4254/wjh.v4.i9.256.


  244. Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma
    Roma J, Balbi E, Pacheco-Moreira L, Zyngier I, Araujo A, Agoglia L, Steinbruck K, Velaverde LG, Martinho JM. Transplant Proc. 2012 Oct;44(8):2423-7. doi: 10.1016/j.transproceed.2012.07.026.


  245. Clinical profile and liver explant findings in patients with and without pretransplant downstaging for hepatocellular carcinoma
    Felga G, Evangelista AS, Salvalaggio PR, Curvelo LA, Della Guardia B, Almeida MD, Afonso RC, Ferraz-Neto BH. Transplant Proc. 2012 Oct;44(8):2399-402. doi: 10.1016/j.transproceed.2012.07.135.


  246. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma
    Li JX, Wu H, Huang JW, Zeng Y. J Formos Med Assoc. 2012 Sep;111(9):510-5. doi: 10.1016/j.jfma.2011.05.016. Epub 2012 Jul 24.


  247. Statins and primary liver cancer: a meta-analysis of observational studies
    Pradelli D, Soranna D, Scotti L, Zambon A, Catapano A, Mancia G, La Vecchia C, Corrao G. Eur J Cancer Prev. 2012 Sep 22. [Epub ahead of print]


  248. An appraisal of radiofrequency ablation and surgical resection for hepatocellular carcinoma: results from the surveillance, epidemiology, and end results registry
    Le M, Nelson R, Lee W, Wiatrek R, Singh G, Garcia-Aguilar J, Kim J. Am Surg. 2012 Oct;78(10):1091-5.


  249. Ten-year Outcomes of Percutaneous Radiofrequency Ablation as First-line Therapy of Early Hepatocellular Carcinoma: Analysis of Prognostic Factors
    Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Gwak GY, Yoo BC. J Hepatol. 2012 Sep 27. pii: S0168-8278(12)00751-9. doi: 10.1016/j.jhep.2012.09.020. [Epub ahead of print]


  250. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria
    Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Br J Surg. 2012 Sep 28. doi: 10.1002/bjs.8915. [Epub ahead of print]


  251. Liver transplantation and expanded Milan criteria: does it really work?
    Ferreira MV, Chaib E, Nascimento MU, Nersessian RS, Setuguti DT, D'Albuquerque LA. Arq Gastroenterol. 2012 Sep;49(3):189-94.


  252. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside
    Aghemo A, Colombo M. Semin Immunopathol. 2012 Jul 22. [Epub ahead of print]


  253. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis
    Saeki I, Terai S, Fujisawa K, Takami T, Yamamoto N, Matsumoto T, Hirose Y, Murata Y, Yamasaki T, Sakaida I. J Gastroenterol. 2012 Sep 26. [Epub ahead of print]


  254. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma according to Child Pugh Classification
    Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Takahashi S, Ishikawa M, Kakizawa H, Awai K, Chayama K. J Gastroenterol Hepatol. 2012 Sep 28. doi: 10.1111/j.1440-1746.2012.07276.x. [Epub ahead of print]


  255. The Effectiveness of Current Acute Variceal Bleed Treatments in Unselected Cirrhotic Patients: Refining Short-Term Prognosis and Risk Factors
    Amitrano L, Guardascione MA, Manguso F, Bennato R, Bove A, Denucci C, Lombardi G, Martino R, Menchise A, Orsini L, Picascia S, Riccio E. Am J Gastroenterol. 2012 Sep 25. doi: 10.1038/ajg.2012.313. [Epub ahead of print]


  256. Thrombocytopenia in Relation to Tumor Size in Patients with Hepatocellular Carcinoma
    Carr BI, Guerra V, Pancoska P. Oncology. 2012 Sep 18;83(6):339-345. [Epub ahead of print]


  257. Liver Stiffness Measurement by Transient Elastography As a Predictor on Posthepatectomy Outcomes
    Wong JS, Wong GL, Chan AW, Wong VW, Cheung YS, Chong CN, Wong J, Lee KF, Chan HL, Lai PB. Ann Surg. 2012 Sep 21. [Epub ahead of print]


  258. Radioembolization for Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Liver Function on Systemic Treatment Options at Disease Progression
    Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, Riaz A, Gupta R, Vouche M, Gates VL, Miller FH, Omary RA, Salem R. J Hepatol. 2012 Sep 18. pii: S0168-8278(12)00692-7. doi: 10.1016/j.jhep.2012.09.003. [Epub ahead of print]


  259. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: Comparison with other liver cancers
    Lee JI, Lee JW, Kim JM, Kim JK, Chung HJ, Kim YS. World J Gastroenterol. 2012 Sep 14;18(34):4751-7.


  260. A single determination of C-reactive protein at the time of diagnosis predicts long term outcome of patients with hepatocellular carcinoma
    Sieghart W, Pinter M, Hucke F, Graziadei I, Schöniger-Hekele M, Müller C, Vogel W, Trauner M, Peck-Radosavljevic M. Hepatology. 2012 Sep 7. doi: 10.1002/hep.26057. [Epub ahead of print]


  261. Comparison Between Living Donor Liver Transplantation Recipients Who Met the Milan and UCSF Criteria After Successful Downstaging Therapies
    Lei J, Yan L. J Gastrointest Surg. 2012 Sep 5. [Epub ahead of print]


  262. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic
    Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, Zarrinpar A, Petrowsky H, Farmer D, Yersiz H, Xia V, Hiatt JR, Busuttil RW. Ann Surg. 2012 Oct;256(4):624-33.


  263. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis
    Shimizu M, Tanaka T, Moriwaki H. Semin Immunopathol. 2012 Sep 4. [Epub ahead of print]


  264. Improved Long-Term Survival after Major Resection for Hepatocellular Carcinoma: A Multicenter Analysis Based on a New Definition of Major Hepatectomy
    Andreou A, Vauthey JN, Cherqui D, Zimmitti G, Ribero D, Truty MJ, Wei SH, Curley SA, Laurent A, Poon RT, Belghiti J, Nagorney DM, Aloia TA; From the International Cooperative Study Group on Hepatocellular Carcinoma. J Gastrointest Surg. 2012 Sep 5. [Epub ahead of print]


  265. Screening for Extrahepatic Metastases by Additional Staging Modalities is Required for Hepatocellular Carcinoma Patients Beyond Modified UICC Stage T1
    Yi J, Gwak GY, Sinn DH, Kim YJ, Kim HN, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Hepatogastroenterology. 2012 Aug 22;60(122). doi: 10.5754/hge12597. [Epub ahead of print]


  266. Influence of Nonclinical Factors on Choice of Therapy for Early Hepatocellular Carcinoma
    Nathan H, Segev DL, Bridges JF, Massie AB, Cameron AM, Hirose K, Schulick RD, Choti MA, Pawlik TM. Ann Surg Oncol. 2012 Sep 1. [Epub ahead of print]


  267. Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation
    Wu WC, Chiou YY, Hung HH, Kao WY, Chou YH, Su CW, Wu JC, Huo TI, Huang YH, Lee KC, Lin HC, Lee SD. J Clin Gastroenterol. 2012 Oct;46(9):789-795.


  268. Targeted agents and systemic therapy in hepatocellular carcinoma
    Ang C, O'Reilly EM, Abou-Alfa GK. Recent Results Cancer Res. 2013;190:225-46.


  269. Multidisciplinary management of hepatocellular carcinoma
    Kaseb AO, Abaza YM, Roses RE. Recent Results Cancer Res. 2013;190:247-59.


  270. Established and Novel Imaging Biomarkers for Assessing Response to Therapy in Hepatocellular Carcinoma
    Jiang T, Zhu AX, Sahani DV. J Hepatol. 2012 Aug 31. [Epub ahead of print]


  271. Cirrhosis and microvascular invasion predict outcomes in hepatocellular carcinoma
    Barreto SG, Brooke-Smith M, Dolan P, Wilson TG, Padbury RT, Chen JW. ANZ J Surg. 2012 Sep 3. doi: 10.1111/j.1445-2197.2012.06196.x. [Epub ahead of print]


  272. Histopathology of hepatocellular carcinoma
    Paradis V. Recent Results Cancer Res. 2013;190:21-32.


  273. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma
    Memon K, Lewandowski RJ, Riaz A, Salem R. Recent Results Cancer Res. 2013;190:207-24.


  274. Transarterial therapies for hepatocellular carcinoma
    Tsochatzis EA, Fatourou EM, Triantos CK, Burroughs AK. Recent Results Cancer Res. 2013;190:195-206.


  275. Hepatocellular carcinoma treated with transarterial chemoembolization: Evaluation with parametric contrast-enhanced ultrasonography
    Moschouris H, Malagari K, Marinis A, Kornezos I, Stamatiou K, Nikas G, Papadaki MG, Gkoutzios P. World J Radiol. 2012 Aug 28;4(8):379-86.


  276. Hepatocellular cancer and liver transplantation: a Western experience
    Lerut J, Julliard O, Ciccarelli O, Lannoy V, Gofette P. Recent Results Cancer Res. 2013;190:127-44.


  277. Transplantation for hepatocellular carcinoma: the north american experience
    Earl TM, Chapman WC. Recent Results Cancer Res. 2013;190:145-64.


  278. Living donor liver transplantation for hepatocellular carcinoma
    Lee SG, Moon DB. Recent Results Cancer Res. 2013;190:165-79.


  279. Imaging of hepatocellular carcinoma: current concepts
    Parikh A, Taouli B. Recent Results Cancer Res. 2013;190:33-55.


  280. Epigenetics of hepatocellular carcinoma: a new horizon
    Liu WR, Shi YH, Peng YF, Fan J. Chin Med J (Engl). 2012 Jul;125(13):2349-60.


  281. Gender Differences in Patient Receiving Liver Transplantation for Viral Hepatitis
    Rifai K, Hadem J, Wiegand J, Potthoff A, Pischke S, Klempnauer J, Strassburg C, Wedemeyer H, Manns MP, Tillmann HL. Z Gastroenterol. 2012 Aug;50(8):760-765. Epub 2012 Aug 15.


  282. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma
    Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS. Cytokine. 2012 Aug 17. [Epub ahead of print]


  283. Incidence of Hepatocellular Carcinoma among US Patients with Cirrhosis of Viral or Non-Viral Etiologies
    Mair RD, Valenzuela A, Ha NB, Ayoub WS, Daugherty T, Lutchman GA, Garcia G, Ahmed A, Nguyen MH. Clin Gastroenterol Hepatol. 2012 Aug 15. [Epub ahead of print]


  284. New concepts and best practices for management of pre- and post-transplantation cancer
    Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, Del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI, Jara P, Morales JM, Navarro M, Oppenheimer F, Prieto M, Pulpón LA, Rimola A, Román A, Serón D, Ussetti P; ATOS Working Group. Transplant Rev (Orlando). 2012 Aug 14. [Epub ahead of print]


  285. Hepatocellular carcinoma: natural history, current management, and emerging tools
    Tinkle CL, Haas-Kogan D. Biologics. 2012;6:207-19. Epub 2012 Jul 17.


  286. Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma
    Xu G, Qi FZ, Zhang JH, Cheng GF, Cai Y, Miao Y. World J Surg Oncol. 2012 Aug 16;10(1):163. [Epub ahead of print]


  287. Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: A phase II study
    Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Hepatology. 2012 Aug 22. doi: 10.1002/hep.26014. [Epub ahead of print]


  288. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy
    Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC, Tseng PL, Hu TH. J Antimicrob Chemother. 2012 Aug 16. [Epub ahead of print]


  289. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma
    Kuske L, Mensen A, Mã Llhaupt B, Negro F, Semela D, Moradpour D, Malã P, Heim M, Malinverni R, Cerny A, Dufour J. Swiss Med Wkly. 2012 Aug 6;142:0. doi: 10.4414/smw.2012.13651.


  290. Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST
    Syha R, Ketelsen D, Heller S, Schmehl J, Mangold S, Heuschmid M, Springer F, Claussen CD, Brechtel K. Eur J Gastroenterol Hepatol. 2012 Aug 4. [Epub ahead of print]


  291. Diabetes, Body Mass Index, and Outcomes in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation
    Siegel AB, Lim EA, Wang S, Brubaker W, Rodriguez RD, Goyal A, Jacobson JS, Hershman DL, C Verna E, Zaretsky J, Halazun K, Dove L, Brown RS Jr, Neugut AI, Kato T, Remotti H, Coppleson YJ, Emond JC. Transplantation. 2012 Aug 2. [Epub ahead of print]


  292. Can propranalol prevent hepatocellular carcinoma?
    London WT, McGlynn KA. Cancer Prev Res (Phila). 2012 Aug;5(8):989-91.


  293. Structure-Activity Relationships in the Development of Allosteric Hepatitis C Virus RNA-Dependent RNA Polymerase Inhibitors: Ten Years of Research
    Haudecoeur R, Peuchmaur M, Ahmed-Belkacem A, Pawlotsky JM, Boumendjel A. Med Res Rev. 2012 Aug 14. doi: 10.1002/med.21271. [Epub ahead of print]


  294. What's New in Transarterial Therapies for Hepatocellular Carcinoma?
    May BJ, Murthy R, Madoff DC. Gastrointest Cancer Res. 2012 May;5(3 Supplement 1):S14-S19.


  295. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation
    Staufer K, Fischer L, Seegers B, Vettorazzi E, Nashan B, Sterneck M. Transpl Int. 2012 Aug 6. doi: 10.1111/j.1432-2277.2012.01540.x. [Epub ahead of print]


  296. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis
    Dhir M, Lyden ER, Smith LM, Are C. HPB (Oxford). 2012 Sep;14(9):635-45. doi: 10.1111/j.1477-2574.2012.00500.x. Epub 2012 Jun 19.


  297. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
    Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M. Hepatology. 2012 Aug 13. doi: 10.1002/hep.25956. [Epub ahead of print]


  298. "Knowledge into action" - Exploration of an appropriate approach for constructing evidence-based clinical practice guidelines for hepatocellular carcinoma
    Song PP, Gao JJ, Kokudo N, Dong JH, Tang W. Biosci Trends. 2012 Jun;6(3):147-52.


  299. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma
    Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, Koike K, Nishino H, Tajiri H. Br J Cancer. 2012 Aug 9. doi: 10.1038/bjc.2012.354. [Epub ahead of print]


  300. Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K. Oncology. 2012 Aug 11;83(4):192-200. [Epub ahead of print]


  301. Epigenetics of hepatocellular carcinoma: a new horizon
    Liu WR, Shi YH, Peng YF, Fan J. Chin Med J (Engl). 2012 Jul;125(13):2349-60.


  302. Alpha-Fetoprotein and Novel Tumor Biomarkers as Predictors of Hepatocellular Carcinoma Recurrence after Surgery: A Brilliant Star Raises Again
    Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Int J Hepatol. 2012;2012:893103. Epub 2012 Jun 27.


  303. Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients
    Hikita H, Nakagawa H, Tateishi R, Masuzaki R, Enooku K, Yoshida H, Omata M, Soroida Y, Sato M, Gotoh H, Suzuki A, Iwai T, Yokota H, Koike K, Yatomi Y, Ikeda H. J Gastroenterol. 2012 Jul 12. [Epub ahead of print]


  304. Hepatocellular carcinoma predicts in-hospital mortality from acute variceal hemorrhage among patients with cirrhosis
    Singal AK, Jampana SC, Singal V, Kuo YF. J Clin Gastroenterol. 2012 Aug;46(7):613-9.


  305. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation
    Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS Jr, Saab S, Shiffman ML, Al-Osaimi AM, Kulik L, Gillespie BW, Everhart JE; A2ALL Study. Hepatology. 2012 Jul 23. doi: 10.1002/hep.25976. [Epub ahead of print]


  306. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients
    Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Huo TI. Aliment Pharmacol Ther. 2012 Jul 22. doi: 10.1111/j.1365-2036.2012.05226.x. [Epub ahead of print]


  307. Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study
    Motosugi U, Ichikawa T, Koshiishi T, Sano K, Morisaka H, Ichikawa S, Enomoto N, Matsuda M, Fujii H, Araki T. Eur Radiol. 2012 Jul 20. [Epub ahead of print]


  308. Assessment of Preoperative Magnetic Resonance Imaging Staging in Patients With Hepatocellular Carcinoma Undergoing Resection Compared With the Seventh American Joint Committee on Cancer System
    An C, Choi GH, Lee HS, Kim MJ. Invest Radiol. 2012 Jul 18. [Epub ahead of print]


  309. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal
    Wang Q, Yu T, Yuan Y, Zhuang H, Wang Z, Liu X, Feng M. J Surg Oncol. 2012 Jul 25. doi: 10.1002/jso.23227. [Epub ahead of print]


  310. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review
    Ruggeri M. Risk Manag Healthc Policy. 2012;5:49-54. Epub 2012 Jun 19.


  311. Serum C-reactive protein is a useful biomarker to predict outcomes after liver transplantation in patients with hepatocellular carcinoma
    An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, You YK, Kim DG, Jung ES. Liver Transpl. 2012 Jul 23. doi: 10.1002/lt.23512. [Epub ahead of print]


  312. Some new approaches to the management of hepatocellular carcinoma
    Carr BI. Semin Oncol. 2012 Aug;39(4):369-73.


  313. Hepatocellualar carcinoma serum markers
    Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Semin Oncol. 2012 Aug;39(4):410-33.


  314. Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?
    Morace C, Cucunato M, Bellerone R, De Caro G, Crinò S, Fortiguerra A, Spadaro F, Zirilli A, Alibrandi A, Consolo P, Luigiano C, Resta ML, Ferraù O, Spadaro A. Eur J Intern Med. 2012 Sep;23(6):e157-61. Epub 2012 May 24.


  315. Epidermal Growth Factor 61A>G Polymorphism Is Associated with Risk of Hepatocellular Carcinoma: A Meta-Analysis
    Yang Z, Wu Q, Shi Y, Nie Y, Wu K, Fan D. Genet Test Mol Biomarkers. 2012 Aug 1. [Epub ahead of print]


  316. Causes of and prevention strategies for hepatocellular carcinoma
    Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Semin Oncol. 2012 Aug;39(4):374-83.


  317. Failure Rates in the Hepatocellular Carcinoma Surveillance Process
    Singal AG, Yopp A, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA. Cancer Prev Res (Phila). 2012 Jul 30. [Epub ahead of print]


  318. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Sacco R, Bargellini I, Ginanni B, Bertini M, Faggioni L, Federici G, Romano A, Bertoni M, Metrangolo S, Altomare E, Parisi G, Tumino E, Scaramuzzino A, Bresci G, Bartolozzi C. Expert Rev Anticancer Ther. 2012 Jul;12(7):869-75.


  319. Diagnosis of hepatocellular carcinoma: newer radiological tools
    Lee JM, Yoon JH, Kim KW. Semin Oncol. 2012 Aug;39(4):399-409.


  320. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)
    Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Clin Transl Oncol. 2012 Jul 18. [Epub ahead of print]


  321. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives
    Zhu AX. Semin Oncol. 2012 Aug;39(4):493-502.


  322. Surveillance for hepatocellular carcinoma
    Della Corte C, Colombo M. Semin Oncol. 2012 Aug;39(4):384-98.


  323. The potential for statins in the chemoprevention and management of hepatocellular carcinoma
    Lonardo A, Loria P. J Gastroenterol Hepatol. 2012 Jul 31. doi: 10.1111/j.1440-1746.2012.07232.x. [Epub ahead of print]


  324. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
    Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC, Galmiche A. Int J Cancer. 2012 Apr 19. doi: 10.1002/ijc.27604. [Epub ahead of print]


  325. Expression of FOXJ1 in hepatocellular carcinoma: Correlation with patients' prognosis and tumor cell proliferation
    Chen HW, Huang XD, Li HC, He S, Ni RZ, Chen CH, Peng C, Wu G, Wang GH, Wang YY, Zhao YH, Zhang YX, Shen AG, Wang HM. Mol Carcinog. 2012 Apr 4. doi: 10.1002/mc.21904. [Epub ahead of print]


  326. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma
    Shin HS, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Baatarkhuu O, Ahn SH. J Gastroenterol Hepatol. 2012 Apr 13. doi: 10.1111/j.1440-1746.2012.07145.x. [Epub ahead of print]


  327. Interventional therapies for hepatocellular carcinoma
    Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Cancer Imaging. 2012 Apr 5;12:79-88.


  328. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients
    Jain D, Nayak NC, Saigal S. Eur J Gastroenterol Hepatol. 2012 Apr 8. [Epub ahead of print]


  329. New developments in the treatment of hepatic tumors
    Di Carlo I, Toro A. Future Oncol. 2012 Apr;8(4):391-4.


  330. Efficacy and Feasibility of Radiofrequency Ablation for Hepatocellular Carcinoma Patients
    Ge YS, Xu GL, Zhang CH, Jia WD, Li JS, Ma JL, Yu JH. Hepatogastroenterology. 2012 Apr 12;59(120). doi: 10.5754/hge12128. [Epub ahead of print]


  331. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits
    Chiu J, Tang YF, Yao TJ, Wong A, Wong H, Leung R, Chan P, Cheung TT, Chan AC, Pang R, Fan ST, Poon R, Yau T. Cancer. 2012 Apr 19. doi: 10.1002/cncr.27543. [Epub ahead of print]


  332. Sorafenib in liver cancer
    Woo HY, Heo J. Expert Opin Pharmacother. 2012 May;13(7):1059-67.


  333. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma
    Xu J, Ding T, He Q, Yu XJ, Wu WC, Jia WH, Yun JP, Zhang Y, Shi M, Shao CK, Pan WD, Yin XY, Min J, Zhuang SM, Zheng L. J Hepatol. 2012 Apr 17. [Epub ahead of print]


  334. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma
    Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, Kim EH, Seong J, Lee DY, Han KH. Liver Int. 2012 Apr 23. doi: 10.1111/j.1478-3231.2012.02811.x. [Epub ahead of print]


  335. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma
    Wang S, Jiang W, Chen X, Zhang C, Li H, Hou W, Liu Z, McNutt MA, Lu F, Li G. J Hepatol. 2012 Apr 17. [Epub ahead of print]


  336. Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein
    Saito Y, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Yamada S, Asanoma M. Hepatol Res. 2012 Apr 4. doi: 10.1111/j.1872-034X.2012.01004.x. [Epub ahead of print]


  337. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis
    Duan F, Wang MQ, Liu FY, Wang ZJ, Song P, Wang Y. Asia Pac J Clin Oncol. 2012 Jun;8(2):156-63. doi: 10.1111/j.1743-7563.2012.01542.x.


  338. Long-term Prognosis in Hepatocellular Carcinoma Patients after Hepatectomy
    Zhou L, Liu C, Meng FD, Qu K, Tian F, Tai MH, Wei JC, Wang RT. Asian Pac J Cancer Prev. 2012;13(2):483-6.


  339. Hepatocellular carcinoma during pregnancy: case report and review of the literature
    Russell P, Sanjay P, Dirkzwager I, Chau K, Johnston P. N Z Med J. 2012 Apr 20;125(1353):141-5.


  340. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma
    Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim YJ. Asia Pac J Clin Oncol. 2012 Jun;8(2):164-71. doi: 10.1111/j.1743-7563.2012.01543.x.


  341. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with viral C cirrhosis
    Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M. Cancer Prev Res (Phila). 2012 Apr 23. [Epub ahead of print]


  342. Epidemiology of viral hepatitis and hepatocellular carcinoma
    El-Serag HB. Gastroenterology. 2012 May;142(6):1264-1273.e1.


  343. Distinctions Between Clinicopathological Factors and Prognosis of Alpha-fetoprotein Negative and Positive Hepatocelluar Carcinoma Patients
    Xu J, Liu C, Zhou L, Tian F, Tai MH, Wei JC, Qu K, Meng FD, Zhang LQ, Wang ZX, Zhang JY, Chang HL, Liu SN, Xu XS, Song YZ, Liu J, Zhang P. Asian Pac J Cancer Prev. 2012;13(2):559-62.


  344. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis
    Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Hepatology. 2012 Apr 26. doi: 10.1002/hep.25814. [Epub ahead of print]


  345. Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma
    Tazi el M, Essadi I, M'rabti H, Touyar A, Errihani PH. N Am J Med Sci. 2011 Apr;3(4):167-75.


  346. Different impact of IL28B polymorphisms on response to peginterferon-? plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b
    Vispo E, Rallon NI, Labarga P, Barreiro P, Benito JM, Soriano V. J Clin Virol. 2012 Jun 20. [Epub ahead of print]


  347. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria
    Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Wolf P, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazoullières O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D; Liver Transplantation French Study group. Gastroenterology. 2012 Jun 29. [Epub ahead of print]


  348. Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan(®))
    Jung KS, Kim SU, Choi GH, Park JY, Park YN, Kim DY, Ahn SH, Chon CY, Kim KS, Choi EH, Choi JS, Han KH. Ann Surg Oncol. 2012 Jul 3. [Epub ahead of print]


  349. Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma
    Chen W, Tomlinson G, Krahn M, Heathcote J. J Viral Hepat. 2012 Aug;19(8):574-80. doi: 10.1111/j.1365-2893.2012.01583.x. Epub 2012 Feb 1.


  350. Update on yttrium-90-based radio-embolization for treatment of hepatocellular carcinoma
    Kan RW, Tsang SH, Poon RT, Cheung TT. ANZ J Surg. 2012 Jul 3. doi: 10.1111/j.1445-2197.2012.06121.x. [Epub ahead of print]


  351. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans
    Sarkar M, Stewart S, Yu A, Chen MS, Nguyen TT, Khalili M. J Viral Hepat. 2012 Aug;19(8):594-600. doi: 10.1111/j.1365-2893.2011.01577.x. Epub 2012 Jan 28.


  352. Obesity-related hepatocellular carcinoma: roles of risk factors altered in obesity
    Shen C, Zhao CY, Zhang R, Qiao L. Front Biosci. 2012 Jun 1;17:2356-70.


  353. Salvage liver transplantation in the treatment of hepatocellular carcinoma: A Meta-analysis
    Li HY, Wei YG, Yan LN, Li B. World J Gastroenterol. 2012 May 21;18(19):2415-22.


  354. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma
    Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade S, Goldwasser F. PLoS One. 2012;7(5):e37563. Epub 2012 May 30.


  355. Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma
    Nagai H, Mukozu T, Matsui D, Kanekawa T, Kanayama M, Wakui N, Momiyama K, Shinohara M, Iida K, Ishii K, Igarashi Y, Sumino Y. Clin Dev Immunol.2012;2012:607851. Epub 2012 May 14.


  356. Genomics and HCV infection: progression of fibrosis and treatment response
    Estrabaud E, Vidaud M, Marcellin P, Asselah T.J Hepatol. 2012 May 30. [Epub ahead of print]


  357. Biomarkers for hepatocellular carcinoma
    Behne T, Copur MS. Int J Hepatol. 2012;2012:859076. Epub 2012 May 10.


  358. Hepatocellular carcinoma: focus on different aspects of management
    Waly Raphael S, Yangde Z, Yuxiang C. ISRN Oncol. 2012;2012:421673. Epub 2012 May 13.


  359. Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients
    Signoriello S, Annunziata A, Lama N, Signoriello G, Chiodini P, De Sio I, Daniele B, Di Costanzo GG, Calise F, Olivieri G, Castaldo V, Lanzetta R, Piai G, Marone G, Visconti M, Fusco M, Di Maio M, Perrone F, Gallo C, Gaeta GB. ScientificWorldJournal. 2012;2012:564706. Epub 2012 May 3.


  360. Concomitant lung metastasis in patients with advanced hepatocellular carcinoma
    Yang T, Lu JH, Lin C, Shi S, Chen TH, Zhao RH, Wang Y, Wu MC. World J Gastroenterol. 2012 May 28;18(20):2533-9.


  361. Socioeconomic status and hepatocellular carcinoma in the United States
    Shebl FM, Capo-Ramos DE, Graubard BI, McGlynn KA, Altekruse SF. Cancer Epidemiol Biomarkers Prev. 2012 Jun 5. [Epub ahead of print]


  362. Screening for hepatocellular carcinoma: The rationale for the AASLD recommendations
    Sherman M, Bruix J, Porayko M, Tran T; for the AASLD Practice Guidelines Committee. Hepatology. 2012 Jun 11. doi: 10.1002/hep.25869. [Epub ahead of print]


  363. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma
    Qiao CX, Zhai XF, Ling CQ, Lang QB, Dong HJ, Liu Q, Li MD. World J Gastroenterol. 2012 Jun 7;18(21):2689-94.


  364. Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy
    Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL. Oncologist. 2012 Jun 6. [Epub ahead of print]


  365. Hepatocellular Carcinoma: Important Biomarkers and their Significance in Molecular Diagnostics and Therapy
    Sengupta B, Siddiqi SA. Curr Med Chem. 2012 Jun 7. [Epub ahead of print]


  366. Resection margin in hepatectomy for hepatocellular carcinoma: a systematic review
    Tang YH, Wen TF, Chen X. Hepatogastroenterology. 2012 Jul;59(117):1393-7. doi: 10.5754/hge10600.


  367. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma
    Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, Yee HT. BMC Gastroenterol. 2012 Jun 8;12(1):64. [Epub ahead of print]


  368. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma
    Yaprak O, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y, Tokat Y. Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):256-61.


  369. Outcome of hepatectomy in hepatocellular carcinoma patients aged 80 years and older
    Tsujita E, Utsunomiya T, Yamashita Y, Ohta M, Tagawa T, Matsuyama A, Okazaki J, Yamamoto M, Tsutsui S, Ishida T. Hepatogastroenterology. 2012 Jul;59(117):1553-5. doi: 10.5754/hge09485.


  370. Living donor versus deceased donor liver transplantation for hepatocellular carcinoma: A meta-analysis
    Liang W, Wu L, Ling X, Schroder PM, Ju W, Wang D, Shang Y, Kong Y, Guo Z, He X. Liver Transpl. 2012 Jun 9. doi: 10.1002/lt.23490. [Epub ahead of print]


  371. Prognostic Factors in Hepatitis C Patients with a Single Small Hepatocellular Carcinoma after Radiofrequency Ablation
    Toshikuni N, Takuma Y, Goto T, Yamamoto H. Hepatogastroenterology. 2012 Jun 8;59(120). doi: 10.5754/hge12394. [Epub ahead of print]


  372. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B
    Chon YE, Jung ES, Park JY, Kim do Y, Ahn SH, Han KH, Chon CY, Jung KS, Kim SU. J Clin Gastroenterol. 2012 Jul;46(6):518-25.


  373. Diabetes worsens the surgical outcomes in cirrhotic patients with hepatocellular carcinoma
    Ting CT, Chen RC, Chen CC, Liu MH, Chu D, Kuo NW. Tohoku J Exp Med. 2012;227(1):73-81.


  374. Family history influences the early onset of hepatocellular carcinoma
    Park CH, Jeong SH, Yim HW, Kim JD, Bae SH, Choi JY, Yoon SK. World J Gastroenterol. 2012 Jun 7;18(21):2661-7.


  375. First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study
    Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA. Int J Clin Pract. 2012 Jul;66(7):675-683. doi: 10.1111/j.1742-1241.2012.02940.x.


  376. A novel and validated prognostic index in hepatocellular carcinoma: the Inflammation Based Index (IBI)
    Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R. J Hepatol. 2012 Jun 22. [Epub ahead of print]


  377. Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial
    Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM; on behalf of the SHARP Investigators Study Group. J Hepatol. 2012 Jun 19. [Epub ahead of print]


  378. A Randomized Controlled Trial of Radiofrequency Ablation and Surgical Resection in the Treatment of Small Hepatocellular Carcinoma
    Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. J Hepatol. 2012 May 22. [Epub ahead of print]


  379. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18)
    Mikoshiba N, Tateishi R, Tanaka M, Sakai T, Blazeby JM, Kokudo N, Koike K, Kazuma K. Health Qual Life Outcomes. 2012 May 31;10(1):58. [Epub ahead of print]


  380. Liver resection for complicated hepatocellular carcinoma: Challenges but opportunity for long-term survivals
    Huang JF, Wu SM, Wu TH, Lee CF, Wu TJ, Yu MC, Chan KM, Lee WC. J Surg Oncol. 2012 May 30. doi: 10.1002/jso.23172. [Epub ahead of print]


  381. Pilot prognostic model of extremely poor survival among high-risk hepatocellular carcinoma patients
    Wray CJ, Harvin JA, Silberfein EJ, Ko TC, Kao LS. Cancer. 2012 May 30. doi: 10.1002/cncr.27649. [Epub ahead of print]


  382. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems
    Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Loong CC, Chiou YY, Huo TI. Dig Liver Dis. 2012 May 28. [Epub ahead of print]


  383. Liver transplantation for hepatocellular carcinoma: Time for an international consensus
    Decaens T. Clin Res Hepatol Gastroenterol. 2012 May 23. [Epub ahead of print]


  384. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience
    Scandurra G, Aiello RA, Alì M, Taibi E, Sanò MV, Todaro FM, La Rocca R, Licciardello P, Caruso M. Future Oncol. 2012 May;8(5):609-15.


  385. Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort
    Thein HH, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ. Hepatol Res. 2012 Apr 18. doi: 10.1111/j.1872-034X.2012.01037.x. [Epub ahead of print]


  386. Liver Transplantation for Hepatocellular Carcinoma: Long-Term Results Suggest Excellent Outcomes
    Doyle MB, Vachharajani N, Maynard E, Shenoy S, Anderson C, Wellen JR, Lowell JA, Chapman WC. J Am Coll Surg. 2012 May 17. [Epub ahead of print]


  387. Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma
    Shau WY, Shao YY, Yeh YC, Lin ZZ, Kuo R, Hsu CH, Hsu C, Cheng AL, Lai MS. Oncologist. 2012 May 23. [Epub ahead of print]


  388. Patients transplanted for nonalcoholic steatohepatitis (NASH) are at increased risk for post-operative cardiovascular events
    Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Hepatology. 2012 May 21. doi: 10.1002/hep.25855. [Epub ahead of print]


  389. Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma in Interlobar Watershed Zone of Liver: Comparison of Unilateral and Bilateral Chemoembolization
    Chou CT, Huang YC, Lee CW, Lee KW, Chen YL, Chen RC. J Vasc Interv Radiol. 2012 May 18. [Epub ahead of print]


  390. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience
    Scandurra G, Aiello RA, Alì M, Taibi E, Sanò MV, Todaro FM, La Rocca R, Licciardello P, Caruso M. Future Oncol. 2012 May;8(5):609-15.


  391. A Randomized Controlled Trial of Radiofrequency Ablation and Surgical Resection in the Treatment of Small Hepatocellular Carcinoma
    Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. J Hepatol. 2012 May 22. [Epub ahead of print]


  392. Liver Transplantation for Hepatocellular Carcinoma: Long-Term Results Suggest Excellent Outcomes
    Doyle MB, Vachharajani N, Maynard E, Shenoy S, Anderson C, Wellen JR, Lowell JA, Chapman WC. J Am Coll Surg. 2012 May 17. [Epub ahead of print]


  393. Risk factors of hepatocellular carcinoma - current status and perspectives
    Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J, Xiang YB. Asian Pac J Cancer Prev. 2012;13(3):743-52.


  394. Obesity-related hepatocellular carcinoma: roles of risk factors altered in obesity
    Shen C, Zhao CY, Zhang R, Qiao L. Front Biosci. 2012 Jun 1;17:2356-70.


  395. Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma
    Shau WY, Shao YY, Yeh YC, Lin ZZ, Kuo R, Hsu CH, Hsu C, Cheng AL, Lai MS. Oncologist. 2012 May 23. [Epub ahead of print]


  396. Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis
    Yan S, Xu D, Sun B. Dig Dis Sci. 2012 May 15. [Epub ahead of print]


  397. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems
    Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Loong CC, Chiou YY, Huo TI. Dig Liver Dis. 2012 May 28. [Epub ahead of print]


  398. Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort
    Thein HH, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ. Hepatol Res. 2012 Apr 18. doi: 10.1111/j.1872-034X.2012.01037.x. [Epub ahead of print]


  399. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
    Farrell GC, van Rooyen D, Gan L, Chitturi S. Gut Liver. 2012 Apr;6(2):149-71. Epub 2012 Apr 17.


  400. Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma?
    Cupino AC, Hair CD, Angle JF, Caldwell SH, Rich TA, Berg CL, Northup PG, Al-Osaimi AM, Argo CK. Gastrointest Cancer Res. 2012 Jan;5(1):13-7.


  401. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma
    Woo HY, Heo J, Yoon KT, Kim GH, Kang DH, Song GA, Cho M. Scand J Gastroenterol. 2012 Jul;47(7):809-19. Epub 2012 May 8.


  402. Does transient elastography (FibroScan(®) ) have a role in decision making in hepatocellular carcinoma?
    Pesce A, Scilletta R, Branca A, Nigro L, Montineri A, Larocca L, Fatuzzo F, Castaing M, Puleo S. HPB (Oxford). 2012 Jun;14(6):403-8. doi: 10.1111/j.1477-2574.2012.00465.x. Epub 2012 Mar 28.


  403. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice
    Di Costanzo GG, Tortora R, Iodice L, Lanza AG, Lampasi F, Tartaglione MT, Picciotto FP, Mattera S, De Luca M. Dig Liver Dis. 2012 May 10. [Epub ahead of print]


  404. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
    Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC, Galmiche A. Int J Cancer. 2012 Apr 19. doi: 10.1002/ijc.27604. [Epub ahead of print]


  405. Expression of FOXJ1 in hepatocellular carcinoma: Correlation with patients' prognosis and tumor cell proliferation
    Chen HW, Huang XD, Li HC, He S, Ni RZ, Chen CH, Peng C, Wu G, Wang GH, Wang YY, Zhao YH, Zhang YX, Shen AG, Wang HM. Mol Carcinog. 2012 Apr 4. doi: 10.1002/mc.21904. [Epub ahead of print]


  406. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma
    Shin HS, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Baatarkhuu O, Ahn SH. J Gastroenterol Hepatol. 2012 Apr 13. doi: 10.1111/j.1440-1746.2012.07145.x. [Epub ahead of print]


  407. Interventional therapies for hepatocellular carcinoma
    Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Cancer Imaging. 2012 Apr 5;12:79-88.


  408. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients
    Jain D, Nayak NC, Saigal S. Eur J Gastroenterol Hepatol. 2012 Apr 8. [Epub ahead of print]


  409. New developments in the treatment of hepatic tumors
    Di Carlo I, Toro A. Future Oncol. 2012 Apr;8(4):391-4.


  410. Efficacy and Feasibility of Radiofrequency Ablation for Hepatocellular Carcinoma Patients
    Ge YS, Xu GL, Zhang CH, Jia WD, Li JS, Ma JL, Yu JH. Hepatogastroenterology. 2012 Apr 12;59(120). doi: 10.5754/hge12128. [Epub ahead of print]


  411. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits
    Chiu J, Tang YF, Yao TJ, Wong A, Wong H, Leung R, Chan P, Cheung TT, Chan AC, Pang R, Fan ST, Poon R, Yau T. Cancer. 2012 Apr 19. doi: 10.1002/cncr.27543. [Epub ahead of print]


  412. Sorafenib in liver cancer
    Woo HY, Heo J. Expert Opin Pharmacother. 2012 May;13(7):1059-67.


  413. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma
    Xu J, Ding T, He Q, Yu XJ, Wu WC, Jia WH, Yun JP, Zhang Y, Shi M, Shao CK, Pan WD, Yin XY, Min J, Zhuang SM, Zheng L. J Hepatol. 2012 Apr 17. [Epub ahead of print]


  414. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma
    Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, Kim EH, Seong J, Lee DY, Han KH. Liver Int. 2012 Apr 23. doi: 10.1111/j.1478-3231.2012.02811.x. [Epub ahead of print]


  415. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma
    Wang S, Jiang W, Chen X, Zhang C, Li H, Hou W, Liu Z, McNutt MA, Lu F, Li G. J Hepatol. 2012 Apr 17. [Epub ahead of print]


  416. Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein
    Saito Y, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Yamada S, Asanoma M. Hepatol Res. 2012 Apr 4. doi: 10.1111/j.1872-034X.2012.01004.x. [Epub ahead of print]


  417. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis
    Duan F, Wang MQ, Liu FY, Wang ZJ, Song P, Wang Y. Asia Pac J Clin Oncol. 2012 Jun;8(2):156-63. doi: 10.1111/j.1743-7563.2012.01542.x.


  418. Long-term Prognosis in Hepatocellular Carcinoma Patients after Hepatectomy
    Zhou L, Liu C, Meng FD, Qu K, Tian F, Tai MH, Wei JC, Wang RT. Asian Pac J Cancer Prev. 2012;13(2):483-6.


  419. Hepatocellular carcinoma during pregnancy: case report and review of the literature
    Russell P, Sanjay P, Dirkzwager I, Chau K, Johnston P. N Z Med J. 2012 Apr 20;125(1353):141-5.


  420. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma
    Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim YJ. Asia Pac J Clin Oncol. 2012 Jun;8(2):164-71. doi: 10.1111/j.1743-7563.2012.01543.x.


  421. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with viral C cirrhosis
    Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M. Cancer Prev Res (Phila). 2012 Apr 23. [Epub ahead of print]


  422. Epidemiology of viral hepatitis and hepatocellular carcinoma
    El-Serag HB. Gastroenterology. 2012 May;142(6):1264-1273.e1.


  423. Distinctions Between Clinicopathological Factors and Prognosis of Alpha-fetoprotein Negative and Positive Hepatocelluar Carcinoma Patients
    Xu J, Liu C, Zhou L, Tian F, Tai MH, Wei JC, Qu K, Meng FD, Zhang LQ, Wang ZX, Zhang JY, Chang HL, Liu SN, Xu XS, Song YZ, Liu J, Zhang P. Asian Pac J Cancer Prev. 2012;13(2):559-62.


  424. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis
    Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Hepatology. 2012 Apr 26. doi: 10.1002/hep.25814. [Epub ahead of print]


  425. Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma
    Tazi el M, Essadi I, M'rabti H, Touyar A, Errihani PH. N Am J Med Sci. 2011 Apr;3(4):167-75.


  426. Prevention of hepatocellular carcinoma: a concise review of contemporary issues
    Wong VW, Chan HL. Ann Hepatol. 2012 May;11(3):284-93.


  427. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis
    Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F, Wu E. Eur J Cancer. 2012 Mar 27. [Epub ahead of print]


  428. Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib
    Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C, Peck-Radosavljevic M, Sieghart W. Radiology. 2012 Mar 21. [Epub ahead of print]


  429. The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
    Scartozzi M, Faloppi L, Bianconi M, Giampieri R, Maccaroni E, Bittoni A, Del Prete M, Loretelli C, Belvederesi L, Svegliati Baroni G, Cascinu S. PLoS One. 2012;7(3):e32653. Epub 2012 Mar 26.


  430. Liver transplantation for hepatocellular carcinoma: indications, bridge therapy and adjuvant therapy
    Li SF, Hawxby AM, Kanagala R, Wright H, Sebastian A. J Okla State Med Assoc. 2012 Jan;105(1):12-6.


  431. Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
    Torres DM, Williams CD, Harrison SA. Clin Gastroenterol Hepatol. 2012 Mar 22. [Epub ahead of print]


  432. Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection
    Fu X, Wan S, Hann HW, Myers RE, Hann RS, Au J, Chen B, Xing J, Yang H. Eur J Cancer. 2012 Mar 21. [Epub ahead of print]


  433. Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review
    Xie B, Wang DH, Spechler SJ. Dig Dis Sci. 2012 Mar 27. [Epub ahead of print]


  434. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma
    Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Aliment Pharmacol Ther. 2012 Apr 8. doi: 10.1111/j.1365-2036.2012.05089.x. [Epub ahead of print]


  435. Outcome of hepatectomy for hepatocellular carcinoma in patients with renal dysfunction
    Toshima T, Shirabe K, Yoshiya S, Muto J, Ikegami T, Yoshizumi T, Maehara Y. HPB (Oxford). 2012 May;14(5):317-24. doi: 10.1111/j.1477-2574.2012.00452.x.


  436. Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis
    Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F. HPB (Oxford). 2012 May;14(5):325-32. doi: 10.1111/j.1477-2574.2012.00453.x. Epub 2012 Mar 27.


  437. The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma
    Miyagi S, Kawagishi N, Sekiguchi S, Akamatsu Y, Sato K, Takeda I, Kobayashi Y, Tokodai K, Fujimori K, Satomi S. Transplant Proc. 2012 Apr;44(3):797-801.


  438. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma
    Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ, Lam VW. HPB (Oxford). 2012 May;14(5):285-90. doi: 10.1111/j.1477-2574.2012.00446.x. Epub 2012 Feb 28.


  439. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease
    Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Arq Gastroenterol. 2012 Mar;49(1):89-96.


  440. The risk factors for early infection in adult living donor liver transplantation recipients
    Soong RS, Chan KM, Chou HS, Wu TJ, Lee CF, Wu TH, Lee WC. Transplant Proc. 2012 Apr;44(3):784-6.


  441. The impact of family history of hepatocellular carcinoma on its patients' survival
    Dai WC, Fan ST, Cheung TT, Chok KSh, Chan AC, Tsang SH, Poon RT, Lo CM. Hepatobiliary Pancreat Dis Int. 2012 Apr;11(2):160-4.


  442. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma
    Yasui K, Hashimoto E, Tokushige K, Koike K, Shima T, Kanbara Y, Saibara T, Uto H, Takami S, Kawanaka M, Komorizono Y, Okanoue T; The Japan NASH Study Group. Hepatol Res. 2012 Feb 29. doi: 10.1111/j.1872-034X.2012.00986.x. [Epub ahead of print]


  443. Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma
    Zhang Y, Zhang S, Wang X, Liu J, Yang L, He S, Chen L, Huang J. J Clin Pathol. 2012 Mar 15. [Epub ahead of print]


  444. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic Fatty liver disease: emerging evidence and mechanisms
    Musso G, Olivetti C, Cassader M, Gambino R. Semin Liver Dis. 2012 Feb;32(1):49-64. Epub 2012 Mar 13.


  445. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil
    Torres DM, Harrison SA. Semin Liver Dis. 2012 Feb;32(1):30-8. Epub 2012 Mar 13.


  446. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients
    Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S, Koike K. J Gastroenterol. 2012 Mar 17. [Epub ahead of print]


  447. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: A propensity score analysis and staging strategy
    Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Lee RC, Lee FY, Huo TI, Lee SD. J Gastroenterol Hepatol. 2012 Apr;27(4):690-699. doi: 10.1111/j.1440-1746.2011.06886.x.


  448. LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy
    Qiu JL, Huang PZ, You JH, Zou RH, Wang L, Hong J, Li BK, Zhou K, Yuan YF. Chin J Cancer. 2012 Mar 16. doi: 10.5732/cjc.011.10426. [Epub ahead of print]


  449. Systematic review: the prognostic role of alpha-fetoprotein following liver transplant for hepatocellular carcinoma
    Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Aliment Pharmacol Ther. 2012 Mar 20. doi: 10.1111/j.1365-2036.2012.05060.x. [Epub ahead of print]


  450. Management of Hepatocellular Carcinoma: Beyond Sorafenib
    Chan SL, Mok T, Ma BB. Curr Oncol Rep. 2012 Mar 21. [Epub ahead of print]


  451. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection - Results from a clinic-based longitudinal cohort
    Hann HW, Fu X, Myers RE, Hann RS, Wan S, Kim SH, Au N, Xing J, Yang H. Eur J Cancer. 2012 Mar 19. [Epub ahead of print]


  452. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)
    Pinato DJ, North BV, Sharma R. Br J Cancer. 2012 Mar 20. doi: 10.1038/bjc.2012.92. [Epub ahead of print]


  453. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011
    Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Liver Int. 2012 Mar 20. doi: 10.1111/j.1478-3231.2012.02792.x. [Epub ahead of print]


  454. Clinical prognostic variables in young patients (under 40 years) with hepatitis B virus-associated hepatocellular carcinoma
    Wang Q, Luan W, Villanueva GA, Rahbari NN, Yee HT, Manizate F, Hiotis SP. J Dig Dis. 2012 Apr;13(4):214-8. doi: 10.1111/j.1751-2980.2012.00577.x.


  455. Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus
    Machida K, Chen CL, Liu JC, Kashiwabara C, Feldman D, French SW, Sher L, Hyeongnam JJ, Tsukamoto H. J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:19-22. doi: 10.1111/j.1440-1746.2011.07010.x.


  456. Fibrosis-dependent mechanisms of hepatocarcinogenesis
    Zhang DY, Friedman SL. Hepatology. 2012 Mar 1. doi: 10.1002/hep.25670. [Epub ahead of print]


  457. Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials
    Qu LS, Chen H, Kuai XL, Xu ZF, Jin F, Zhou GX. Hepatol Res. 2012 Feb 15. doi: 10.1111/j.1872-034X.2012.00984.x. [Epub ahead of print]


  458. Role of IL28B Polymorphism in the Development of Hepatitis C Virus-Induced Hepatocellular Carcinoma, Graft Fibrosis, and Posttransplant Antiviral Therapy
    Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, Neuhaus P, Neumann U, Seehofer D. Transplantation. 2012 Mar 27;93(6):644-9.


  459. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma
    Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):173-85.


  460. Screening for liver cancer: the rush to judgment
    Lederle FA, Pocha C. Ann Intern Med. 2012 Mar 6;156(5):387-9.


  461. Usefulness of Alpha-fetoprotein Response in Patients Treated with Sorafenib for Advanced Hepatocellular Carcinoma
    Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A. J Hepatol. 2012 Mar 10. [Epub ahead of print]


  462. Neuromuscular disorders associated with hepatitis B virus infection
    Stübgen JP. J Clin Neuromuscul Dis. 2011 Sep;13(1):26-37.


  463. Administration of bisphosphonates for malignant hepatic tumor with hypercalcemia
    Oida T, Mimatsu K, Kano H, Kawasaki A, Kuboi Y, Fukino N, Kida K, Amano S. Hepatogastroenterology. 2012 Mar-Apr;59(114):444-7. doi: 10.5754/hge09326.


  464. Imaging predictors of response to transarterial chemoembolization in patients with hepatocellular carcinoma: Radiologic-pathologic correlation
    Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY. Liver Transpl. 2012 Feb 17. doi: 10.1002/lt.23413. [Epub ahead of print]


  465. Hepatocellular carcinoma: towards personalized medicine
    Miki D, Ochi H, Nelson Hayes C, Aikata H, Chayama K. Cancer Sci. 2012 Feb 16. doi: 10.1111/j.1349-7006.2012.02242.x. [Epub ahead of print]


  466. Living donor liver transplantation for hepatocellular carcinoma: the impact of neo-adjuvant treatments on the long term results
    Di Sandro S, Giacomoni A, Slim A, Lauterio A, Mangoni I, Mihaylov P, Pirotta V, Aseni P, De Carlis L. Hepatogastroenterology. 2012 Mar-Apr;59(114):505-10. doi: 10.5754/hge11225.


  467. Intersecting pathways in inflammation and cancer: Hepatocellular carcinoma as a paradigm
    Wai PY, Kuo PC. World J Clin Oncol. 2012 Feb 10;3(2):15-23.


  468. Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization
    Shi XJ, Jin X, Wang MQ, Wei LX, Ye HY, Liang YR, Luo Y, Dong JH. Chin Med J (Engl). 2012 Jan;125(2):197-202.


  469. Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma
    Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK. Oncology. 2012 Feb 17;82(2):119-125. [Epub ahead of print]


  470. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis
    Chen YY, Yen HH, Chou KC, Wu SS. World J Gastroenterol. 2012 Feb 7;18(5):466-71.


  471. Integrative genomics: Liver regeneration and hepatocellular carcinoma
    Coban Z, Barton MC. J Cell Biochem. 2012 Feb 17. doi: 10.1002/jcb.24104. [Epub ahead of print]


  472. Hepatocellular carcinoma
    Forner A, Llovet JM, Bruix J. Lancet. 2012 Feb 17. [Epub ahead of print]


  473. Safety of synchronous hepatectomy and splenectomy for patients with hepatocellular carcinoma and hypersplenism
    Wang C, Li C, Wen TF, Yan LN, Li B, Liang GL, Li KW. Hepatogastroenterology. 2012 Mar-Apr;59(114):526-8. doi: 10.5754/hge11260.


  474. C-reactive protein predicts short-term mortality in patients with cirrhosis
    Cervoni JP, Thévenot T, Weil D, Muel E, Barbot O, Sheppard F, Monnet E, Di Martino V. J Hepatol. 2012 Feb 5. [Epub ahead of print]


  475. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma
    Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Eur J Cancer. 2012 Feb 9. [Epub ahead of print]


  476. Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial
    Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Oncologist. 2012 Feb 14. [Epub ahead of print]


  477. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DCBeads. Implications for clinical practice and trial design
    Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. J Hepatol. 2012 Feb 5. [Epub ahead of print]


  478. Molecular targeted therapies for cancer: Sorafenib mono-therapy and its combination with other therapies (Review)
    Ibrahim N, Yu Y, Walsh WR, Yang JL. Oncol Rep. 2012 Feb 6. doi: 10.3892/or.2012.1675. [Epub ahead of print]


  479. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area
    Kang HY, Shin HD, Kim SB, Song IH. Clin Res Hepatol Gastroenterol. 2012 Feb 8. [Epub ahead of print]


  480. Needs for hepatocellular carcinoma control policy in the Asia-pacific region
    Bridges JF, Joy SM, Gallego G, Kudo M, Ye SL, Han KH, Cheng AL, Blauvelt BM. Asian Pac J Cancer Prev. 2011;12(10):2585-91.


  481. Hepatocellular carcinoma in nonalcoholic fatty liver disease: An emerging menace
    Baffy G, Brunt EM, Caldwell SH. J Hepatol. 2012 Feb 9. [Epub ahead of print]


  482. Role of the routine use of chest computed tomography and bone scan in staging workup of hepatocellular carcinoma
    Jin YJ, Lee HC, Lee D, Shim JH, Kim KM, Lim YS, Do KH, Ryu JS. J Hepatol. 2012 Feb 6. [Epub ahead of print]


  483. Hepatitis C: epidemiology, diagnosis, natural history and therapy
    Pol S, Vallet-Pichard A, Corouge M, Mallet VO. Contrib Nephrol. 2012;176:1-9. Epub 2012 Jan 30.


  484. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
    Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, Kato A, Shida T, Okamura D, Miyazaki M. BMC Cancer. 2012 Feb 6;12(1):56. [Epub ahead of print]


  485. Hepatitis C-related liver disease in dialysis patients
    Fabrizi F, Dixit V, Messa P, Martin P. Contrib Nephrol. 2012;176:42-53. Epub 2012 Jan 30.


  486. Antibiotic prophylaxis in transarterial therapy of hepatocellular carcinoma: A meta-analysis
    Wang J, He XD, Zhang YC. Can J Gastroenterol. 2012 Feb;26(2):85-91.


  487. The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility
    Junjie X Dr, Songyao J Dr, Minmin S Dr, Yanyan S Dr, Baiyong S Dr, Xiaxing D Dr, Jiabin J Dr, Xi Z Dr, Hao C Dr. BMC Cancer. 2012 Feb 7;12(1):57. [Epub ahead of print]


  488. Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma
    Winters SD, Jackson S, Armstrong GA, Birchall IW, Lee KH, Low G. Clin Radiol. 2012 Jan 31. [Epub ahead of print]


  489. Non-Invasive Diagnosis of Hepatocellular Carcinoma ≤ 2 cm in Cirrhosis. Diagnostic accuracy Assessing Fat, Capsule and Signal Intensity at Dynamic MRI
    Rimola J, Forner A, Tremosini S, Reig M, Vilana R, Bianchi L, Rodríguez-Lope C, Solé M, Ayuso C, Bruix J. J Hepatol. 2012 Feb 4. [Epub ahead of print]


  490. Diagnostic and Therapeutic Potential of miRNA Signatures in Patients with Hepatocellular Carcinoma
    Borel F, Konstantinova P, Jansen PL. J Hepatol. 2012 Feb 4. [Epub ahead of print]


  491. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization
    Sung PS, Bae SH, Jang JW, Song do S, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK. Korean J Hepatol. 2011 Dec;17(4):299-306. doi: 10.3350/kjhep.2011.17.4.299.


  492. Phase II Study of Concurrent Transarterial Chemoembolization and Sorafenib for Patients with Unresectable Hepatocellular Carcinoma
    Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH. J Hepatol. 2012 Feb 4. [Epub ahead of print]


  493. Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma
    Minami Y, Kudo M. World J Gastroenterol. 2011 Dec 7;17(45):4952-9.


  494. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines
    Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. J Hepatol. 2011 Dec 12. [Epub ahead of print]


  495. Targeting Liver Cancer: First Steps toward a miRacle?
    Schwabe RF, Wang TC. Cancer Cell. 2011 Dec 13;20(6):698-9.


  496. A Meta-Analysis of Array-CGH Studies Implicates Antiviral Immunity Pathways in the Development of Hepatocellular Carcinoma
    Guo X, Yanna, Ma X, An J, Shang Y, Huang Q, Yang H, Chen Z, Xing J. PLoS One. 2011;6(12):e28404. Epub 2011 Dec 12.


  497. Number and Tumor Size Are Not Sufficient Criteria to Select Patients for Liver Transplantation for Hepatocellular Carcinoma
    Piardi T, Gheza F, Ellero B, Woehl-Jaegle ML, Ntourakis D, Cantu M, Marzano E, Audet M, Wolf P, Pessaux P. Ann Surg Oncol. 2011 Dec 17. [Epub ahead of print]


  498. Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma
    Wu TH, Yu MC, Chen TC, Lee CF, Chan KM, Wu TJ, Chou HS, Lee WC, Chen MF. J Surg Oncol. 2012 Jan;105(1):85-90. doi: 10.1002/jso.22060.


  499. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
    Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. Cancer. 2011 Dec 16. doi: 10.1002/cncr.26726. [Epub ahead of print]


  500. Multimodality Treatment with Conventional Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Unresectable Hepatocellular Carcinoma
    Ashoori N, Paprottka P, Trumm C, Bamberg F, Kolligs FT, Rentsch M, Reiser MF, Jakobs TF. Digestion. 2011 Dec 8;85(1):18-26. [Epub ahead of print]


  501. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma
    Zhong JH, Li le Q, Wu LC. Cochrane Database Syst Rev. 2011 Dec 7;12:CD008713.


  502. Beyond
    Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Nakanuma Y, Paradis V, Quaglia A, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ. Am J Clin Pathol. 2012 Jan;137(1):5-9.


  503. Effects of risk factors and ki-67 on rates of recurrence on patients who have undergone liver transplant for hepatocellular carcinoma
    Aktas S, Karakayali H, Moray G, Ozdemir H, Haberal M. Transplant Proc. 2011 Dec;43(10):3807-12.


  504. Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation
    Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Int J Radiat Oncol Biol Phys. 2011 Dec 13. [Epub ahead of print]


  505. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled
    Matsuda Y, Fukumoto M. Med Mol Morphol. 2011 Dec;44(4):183-9. Epub 2011 Dec 17.


  506. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis
    Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. J Cancer Res Clin Oncol. 2011 Dec 18. [Epub ahead of print]


  507. Rate of Tumor Growth Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation in Patients Beyond Milan or UCSF Criteria
    Hanouneh IA, Macaron C, Lopez R, Aucejo F, Zein NN. Transplant Proc. 2011 Dec;43(10):3813-8.


  508. The molecular pathogenesis and clinical implications of hepatocellular carcinoma
    Meguro M, Mizuguchi T, Kawamoto M, Hirata K. Int J Hepatol. 2011;2011:818672. Epub 2011 Dec 4.


  509. Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models
    Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Radiology. 2011 Dec 20. [Epub ahead of print]


  510. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation
    Lai Q, Avolio AW, Manzia TM, Sorge R, Agnes S, Tisone G, Berloco PB, Rossi M. Clin Transplant. 2011 Dec 22. doi: 10.1111/j.1399-0012.2011.01572.x. [Epub ahead of print]


  511. Utilization and Outcomes of Palliative Therapy for Hepatocellular Carcinoma: A Population-based Study in the United States
    Davila JA, Duan Z, McGlynn KA, El-Serag HB. J Clin Gastroenterol. 2012 Jan;46(1):71-7.


  512. Adverse Outcomes in Patients with Postoperative Ascites after Liver Resection for Hepatocellular Carcinoma
    Chan KM, Lee CF, Wu TJ, Chou HS, Yu MC, Lee WC, Chen MF. World J Surg. 2011 Dec 1. [Epub ahead of print]


  513. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? NO
    Heuman DM, Gilles HS, Solomon C, Bajaj JS. Eur J Intern Med. 2012 Jan;23(1):37-9. Epub 2011 Nov 4.


  514. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? Yes.
    Parisi G. Eur J Intern Med. 2012 Jan;23(1):34-6. Epub 2011 Nov 26.


  515. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy
    Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Wu JC, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD. Clin Radiol. 2011 Dec 6. [Epub ahead of print]


  516. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: Is liver resection always contraindicated?
    Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, Guglielmi A. World J Gastroenterol. 2011 Dec 14;17(46):5083-8.


  517. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation
    Kohli V, Singhal A, Elliott L, Jalil S. Transpl Int. 2011 Dec 12. doi: 10.1111/j.1432-2277.2011.01396.x. [Epub ahead of print]


  518. Recurrent Hepatocellular Carcinoma Treated with Sequential Transcatheter Arterial Chemoembolization and RF Ablation versus RF Ablation Alone: A Prospective Randomized Trial
    Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Radiology. 2011 Dec 12. [Epub ahead of print]


  519. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy
    Lencioni R. Crit Rev Oncol Hematol. 2011 Dec 3. [Epub ahead of print]


  520. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
    Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Am J Gastroenterol. 2011 Dec 13. doi: 10.1038/ajg.2011.425. [Epub ahead of print]


  521. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-coinfected patients: Results from ANRS CO13 HEPAVIH
    Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P. J Hepatol. 2011 Dec 12. [Epub ahead of print]


  522. Liver resection for hepatocellular carcinoma: case-matched analysis of laparoscopic versus open resection
    Kim HH, Park EK, Seoung JS, Hur YH, Koh YS, Kim JC, Cho CK, Kim HJ. J Korean Surg Soc. 2011 Jun;80(6):412-9. Epub 2011 Jun 9.


  523. Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none?
    Khalili K, Kyoung Kim T, Jang HJ, Kochak Yazdi L, Guindi M, Sherman M. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24638. [Epub ahead of print]


  524. Multidisciplinary Management of Hepatocellular Carcinoma
    Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Clin Gastroenterol Hepatol. 2011 Nov 11. [Epub ahead of print]


  525. Anti-inflammatory drugs reduce the risk of hepatocellular carcinoma development
    Rino Y, Tarao K.ISRN Oncol. 2011;2011:390676. Epub 2011 Jul 7.


  526. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma
    Unek T, Karademir S, Arslan NC, Egeli T, Atasoy G, Sagol O, Obuz F, Akarsu M, Astarcioglu I. World J Gastroenterol. 2011 Oct 7;17(37):4206-12.


  527. HCC, diet and metabolic factors: Diet and HCC
    Montella M, Crispo A, Giudice A. Hepat Mon. 2011 Mar 1;11(3):159-162.


  528. Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling
    Yang JD, Seol SY, Leem SH, Kim YH, Sun Z, Lee JS, Thorgeirsson SS, Chu IS, Roberts LR, Kang KJ. J Korean Med Sci. 2011 Nov;26(11):1428-38. Epub 2011 Oct 27.


  529. Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma
    Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, Welker M, Shi Y, Peveling-Oberhag J, Polta A, von Wagner M, Radeke HH, Sarrazin C, Trojan J, Zeuzem S, Kronenberger B, Piiper A. PLoS One. 2011;6(10):e26971. Epub 2011 Oct 31.


  530. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development
    Hu L, Zhai X, Liu J, Chu M, Pan S, Jiang J, Zhang Y, Wang H, Chen J, Shen H, Hu Z. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24799. [Epub ahead of print]


  531. Non-alcoholic steatohepatitis: new insights from OMICS studies
    Cécile M, Davide DE, Antonin B, Catherine B, Antoinette L. Curr Pharm Biotechnol. 2011 Nov 25. [Epub ahead of print]


  532. Resection for Hepatocellular Carcinoma: Is it justifiable to restrict this to the AASLD/BCLC criteria?
    Chow PK. J Gastroenterol Hepatol. 2011 Dec 6. doi: 10.1111/j.1440-1746.2011.07034.x. [Epub ahead of print]


  533. Liver resection after downstaging hepatocellular carcinoma with sorafenib
    Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Int J Hepatol. 2011;2011:791013. Epub 2011 Mar 20.


  534. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis
    Wong CM, Wong CC, Lee JM, Fan DN, Au SL, Ng IO. Hepatology. 2011 Dec 2. doi: 10.1002/hep.25512. [Epub ahead of print]


  535. The Outcomes and Safety of Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC)
    Wong H, Tang YF, Yao TJ, Chiu J, Leung R, Chan P, Cheung TT, Chan AC, Pang RW, Poon R, Fan ST, Yau T. Oncologist. 2011 Dec 1. [Epub ahead of print]


  536. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma
    Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura SI, Shiraha H, Kuwaki K, Hagihara H, Ikeda F, Miyake Y, Takaki A, Yamamoto K. J Gastroenterol. 2011 Nov 3. [Epub ahead of print]


  537. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib
    Cabibbo G, Rolle E, De Giorgio M, Genco C, Pressiani T, Spada F, Sacco R; The HCC Working Group. Expert Rev Anticancer Ther. 2011 Aug 26. [Epub ahead of print]


  538. Type 2 Diabetes and hepatocellular carcinoma: A Case-control study in patients with chronic hepatitis B
    Li Q, Li WW, Yang X, Fan WB, Yu JH, Xie SS, Liu L, Ma LX, Chen SJ, Kato N. Int J Cancer. 2011 Nov 2. doi: 10.1002/ijc.27337. [Epub ahead of print]


  539. Clinicopathologic Features and Risk Factors for Extrahepatic Recurrences of Hepatocellular Carcinoma After Curative Resection
    Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E. World J Surg. 2011 Nov 4. [Epub ahead of print]


  540. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report
    Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; on behalf of the OLT for HCC Consensus Group. Lancet Oncol. 2011 Oct 31. [Epub ahead of print]


  541. Stage of hepatocellular carcinoma is associated with periodontitis
    Tamaki N, Takaki A, Tomofuji T, Endo Y, Kasuyama K, Ekuni D, Yasunaka T, Yamamoto K, Morita M. J Clin Periodontol. 2011 Nov;38(11):1015-20. doi: 10.1111/j.1600-051X.2011.01777.x. Epub 2011 Sep 15.


  542. Postoperative infectious and non-infectious complications after hepatectomy for hepatocellular carcinoma
    Kaibori M, Ishizaki M, Matsui K, Kwon AH. Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1747-56. doi: 10.5754/hge10533.


  543. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment
    Toro A, Pulvirenti E, Palermo F, Di Carlo I. Surg Oncol. 2011 Nov 18. [Epub ahead of print]


  544. Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma
    Shao YY, Chen PJ, Lin ZZ, Huang CC, Ding YH, Lee YH, Hsu CH, Cheng AL. Anticancer Res. 2011 Nov;31(11):4007-11.


  545. MRI features of hepatocellular carcinoma expressing progenitor cell markers
    Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, Franceschi S, Montella M, Polesel J, Zucchetto A, La Vecchia C, Negri E, Decarli A. Hepatology. 2011 Nov 16. doi: 10.1002/hep.24794. [Epub ahead of print]


  546. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma
    Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. World J Gastroenterol. 2011 Oct 14;17(38):4258-70.


  547. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection
    Noda T, Yamamoto H, Takemasa I, Yamada D, Uemura M, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. Liver Int. 2011 Aug 11. doi: 10.1111/j.1478-3231.2011.02619.x. [Epub ahead of print]


  548. MRI features of hepatocellular carcinoma expressing progenitor cell markers
    Jeong HT, Kim MJ, Kim YE, Park YN, Choi GH, Choi JS. Liver Int. 2011 Sep 13. doi: 10.1111/j.1478-3231.2011.02640.x. [Epub ahead of print]


  549. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study
    Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T. J Gastroenterol. 2011 Nov 23. [Epub ahead of print]


  550. 65-gene-based risk score classifier predicts overall survival in hepatocellular carcinoma
    Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24813. [Epub ahead of print]


  551. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation
    He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, Yang P, Wang BL, Zhang BH, Zhang JY. BMC Cancer. 2011 Nov 22;11(1):492. [Epub ahead of print]


  552. Subtle Hepatocellular Carcinoma: A Persisting Role for Alpha-Fetoprotein Monitoring in High-Risk Patients with Cirrhosis
    Schlansky B, Dobos N, Zaman A. Case Rep Gastroenterol. 2011 Sep;5(3):565-568. Epub 2011 Oct 1.


  553. Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?
    Berry K, Ioannou GN. Am J Transplant. 2011 Nov 28. doi: 10.1111/j.1600-6143.2011.03853.x. [Epub ahead of print]


  554. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy
    Farinati F, Giacomin A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Eur J Gastroenterol Hepatol. 2011 Nov 18. [Epub ahead of print]


  555. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
    Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F. Invest New Drugs. 2011 Oct 29. [Epub ahead of print]


  556. Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures
    Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. J Epidemiol. 2011 Oct 22. [Epub ahead of print]


  557. Diagnostic and prognostic molecular markers in hepatocellular carcinoma
    Mínguez B, Lachenmayer A. Dis Markers. 2011 Jan 1;31(3):181-90.


  558. Limited Liver Resection: A Good Indication for the Treatment of Hepatocellular Carcinoma in Elderly Patients
    Portolani N, Baiocchi GL, Coniglio A, Tiberio GA, Prestini K, Gheza F, Benetti A, Maria Giulini S. Jpn J Clin Oncol. 2011 Oct 28. [Epub ahead of print]


  559. From liver cirrhosis to HCC
    Bolondi L, Gramantieri L. Intern Emerg Med. 2011 Oct;6 Suppl 1:93-8.


  560. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?
    Wei S, Hao X, Zhan D, Xiong M, Li K, Chen X, Huang Z. J Huazhong Univ Sci Technolog Med Sci. 2011 Oct;31(5):637-41. Epub 2011 Oct 25.


  561. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: Chemoembolization and stent combined with iodine-125 seed
    Chuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, Xiao-Ning L, Li-Gong L. Cancer Biol Ther. 2011 Nov 15;12(10). [Epub ahead of print]


  562. Follow-Up of High-Intensity Focused Ultrasound Treatment for Patients with Hepatocellular Carcinoma
    Xu G, Luo G, He L, Li J, Shan H, Zhang R, Li Y, Gao X, Lin S, Wang G. Ultrasound Med Biol. 2011 Oct 26. [Epub ahead of print]


  563. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal
    Nobili V, Sanyal AJ. J Gastroenterol. 2011 Oct 8. [Epub ahead of print]


  564. MWA Combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma
    Liu C, Liang P, Liu F, Wang Y, Li X, Han Z, Liu C. Int J Hyperthermia. 2011 Oct 3. [Epub ahead of print]


  565. Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma
    Okamura Y, Maeda A, Matsunaga K, Kanemoto H, Uesaka K. J Hepatobiliary Pancreat Sci. 2011 Oct 8. [Epub ahead of print]


  566. Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma
    Antoch G, Roelle G, Ladd SC, Kuehl H, Heusner TA, Sotiropoulos GC, Hilgard P, Forsting M, Verhagen R. Eur J Radiol. 2011 Oct 4. [Epub ahead of print]


  567. Comparative Analysis of the Safety and Efficacy of Transcatheter Arterial Chemoembolization and Yttrium-90 Radioembolization in Patients with Unresectable Hepatocellular Carcinoma
    Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. J Vasc Interv Radiol. 2011 Oct 7. [Epub ahead of print]


  568. AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature
    Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA. Onkologie. 2011;34(10):538-42. Epub 2011 Sep 16.


  569. High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy
    Shao YY, Lin ZZ, Chen TJ, Hsu C, Shen YC, Hsu CH, Cheng AL. Oncology. 2011 Oct 4;81(2):98-103. [Epub ahead of print]


  570. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis
    Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N, Mizushima T, Higashi T, Tanimoto M. Oncology. 2011;81(1):39-44. Epub 2011 Sep 9.


  571. Sorafenib in hepatocellular carcinoma - a post marketing evaluation
    Trojniak MP, Palozzo AC, Mazurek M, Jirillo A. Immunopharmacol Immunotoxicol. 2011 Oct 8. [Epub ahead of print]


  572. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma
    Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Liver Transpl. 2011 Oct;17 Suppl 2:S6-S13. doi: 10.1002/lt.22423.


  573. Surgical and oncologic outcomes following laparoscopic versus open liver resection for hepatocellular carcinoma: A meta-analysis
    Li N, Wu YR, Wu B, Lu MQ. Hepatol Res. 2011 Oct 11. doi: 10.1111/j.1872-034X.2011.00890.x. [Epub ahead of print]


  574. Long-Term Outcome of Percutaneous Ablation in Very Early-Stage Hepatocellular Carcinoma
    Kuang M, Xie XY, Huang C, Wang Y, Lin MX, Xu ZF, Liu GJ, Lu MD. J Gastrointest Surg. 2011 Oct 5. [Epub ahead of print]


  575. Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma
    Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Am J Gastroenterol. 2011 Oct 18. doi: 10.1038/ajg.2011.327. [Epub ahead of print]


  576. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study
    Tomoda T, Nouso K, Sakai A, Ouchida M, Kobayashi S, Miyahara K, Onishi H, Nakamura S, Yamamoto K, Shimizu K. J Gastroenterol Hepatol. 2011 Oct 17. doi: 10.1111/j.1440-1746.2011.06948.x. [Epub ahead of print]


  577. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?
    Landman MP, Feurer ID, Pinson CW, Moore DE. HPB (Oxford). 2011 Nov;13(11):783-91. doi: 10.1111/j.1477-2574.2011.00355.x. Epub 2011 Aug 19.


  578. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review
    Tan CH, Low SC, Thng CH. Int J Hepatol. 2011;2011:519783. Epub 2011 Apr 19.


  579. Chemoembolization for intermediate HCC: Is there proof of survival benefit?
    Forner A, Llovet JM, Bruix J. J Hepatol. 2011 Oct 15. [Epub ahead of print]


  580. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
    Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K. J Gastroenterol Hepatol. 2011 Nov;26(11):1604-11. doi: 10.1111/j.1440-1746.2011.06887.x.


  581. Radiofrequency ablation of hepatocellular carcinoma: a literature review
    Minami Y, Kudo M. Int J Hepatol. 2011;2011:104685. Epub 2011 May 11.


  582. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis
    Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. J Gastroenterol Hepatol. 2011 Oct 17. doi: 10.1111/j.1440-1746.2011.06947.x. [Epub ahead of print]


  583. Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection
    Merchant N, David CS, Cunningham SC. Int J Hepatol. 2011;2011:142085. Epub 2011 Apr 27.


  584. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic
    Schattenberg JM, Schuppan D. Curr Opin Lipidol. 2011 Oct 14. [Epub ahead of print]


  585. Effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
    Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M. Aliment Pharmacol Ther. 2011 Oct 27. doi: 10.1111/j.1365-2036.2011.04896.x. [Epub ahead of print]


  586. Liver transplantation for hepatocellular carcinoma: lessons learned and future directions
    Levi DM, Nishida S. Clin Liver Dis. 2011 Nov;15(4):717-25.


  587. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis
    Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, Wen TF, Xu MQ, Wang WT, Yang JY. World J Gastroenterol. 2011 Sep 14;17(34):3941-7.


  588. Increased HCMV seroprevalence in patients with hepatocellular carcinoma
    Lepiller Q, Tripathy MK, Di Martino V, Kantelip B, Herbein G. Virol J. 2011 Oct 27;8(1):485. [Epub ahead of print]


  589. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma
    Ponziani F, Ojetti V, Tortora A, Di Maurizio L, Purchiaroni F, Gasbarrini A. Expert Opin Drug Metab Toxicol. 2011 Oct 27. [Epub ahead of print]


  590. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
    Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J. World J Gastroenterol. 2011 Sep 14;17(34):3922-32.


  591. Screening for hepatocellular carcinoma
    Lui HF. Int J Hepatol. 2011;2011:363151. Epub 2011 Oct 17.


  592. Non-alcoholic fatty liver disease: is iron relevant?
    O'Brien J, Powell LW. Hepatol Int. 2011 Aug 12. [Epub ahead of print]


  593. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients
    Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM. Antivir Ther. 2011;16(7):959-68.


  594. RPL36 as a prognostic marker in hepatocellular carcinoma
    Song MJ, Jung CK, Park CH, Hur W, Choi JE, Bae SH, Choi JY, Choi SW, Han NI, Yoon SK. Pathol Int. 2011 Nov;61(11):638-44. doi: 10.1111/j.1440-1827.2011.02716.x. Epub 2011 Sep 23.


  595. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence
    Toso C, Mentha G, Majno P. Am J Transplant. 2011 Oct;11(10):2031-5. doi: 10.1111/j.1600-6143.2011.03689.x. Epub 2011 Aug 10.


  596. Epidemiology of the metabolic syndrome in the USA
    McCullough AJ. J Dig Dis. 2011 Oct;12(5):333-40. doi: 10.1111/j.1751-2980.2010.00469.x.


  597. Identification of osteopontin as a novel marker for early hepatocellular carcinoma
    Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Hepatology. 2011 Sep 27. doi: 10.1002/hep.24703. [Epub ahead of print]


  598. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma
    Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, Chen MF. World J Surg Oncol. 2011 Sep 30;9(1):114. [Epub ahead of print]


  599. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
    Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O, Mathurin P. Aliment Pharmacol Ther. 2011 Sep 29. doi: 10.1111/j.1365-2036.2011.04860.x. [Epub ahead of print]


  600. Incidence and Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation in the MELD Era
    Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Dig Dis Sci. 2011 Sep 28. [Epub ahead of print]


  601. Hepatocellular carcinoma confirmation, treatment, and survival in SEER registries, 1992-2008
    Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatology. 2011 Sep 27. doi: 10.1002/hep.24710. [Epub ahead of print]


  602. Hepatocellular Carcinoma
    Hashem B. El-Serag, M.D., M.P.H. N Engl J Med 2011; 365:1118-1127September 22, 2011


  603. Genomic risk of hepatitis C-related hepatocellular carcinoma
    Hoshida Y, Fuchs BC, Tanabe KK. J Hepatol. 2011 Sep 27. [Epub ahead of print]


  604. Efficacy and safety of sorafenib in combination with mTOR inhibitors in recurrent hepatocarcinoma after liver transplant
    Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Liver Transpl. 2011 Sep 19. doi: 10.1002/lt.22434. [Epub ahead of print]


  605. Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study
    Koh WP, Robien K, Wang R, Govindarajan S, Yuan JM, Yu MC. Br J Cancer. 2011 Sep 13. doi: 10.1038/bjc.2011.360. [Epub ahead of print]


  606. Cancer preventive effect of pegylated interferon ?-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis
    Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M; PERFECT Study Group. Hepatol Res. 2011 Oct;41(10):955-964. doi: 10.1111/j.1872-034X.2011.00847.x. Epub 2011 Jun 28.


  607. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors
    Song T, Zhang W, Wu Q, Kong D, Ma W. Eur J Gastroenterol Hepatol. 2011 Sep 21. [Epub ahead of print]


  608. Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score Analysis
    Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Pai JT, Loong CC, Chiou YY, Lee RC, Lee FY, Huo TI, Lee SD. Ann Surg Oncol. 2011 Sep 13. [Epub ahead of print]


  609. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis
    Akima T, Tamano M, Hiraishi H. Hepatol Res. 2011 Oct;41(10):965-70. doi: 10.1111/j.1872-034X.2011.00846.x. Epub 2011 Aug 24.


  610. Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy
    Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC. J Clin Gastroenterol. 2011 Sep 19. [Epub ahead of print]


  611. Chronic liver disease in the Hispanic population of the United States
    Carrion AF, Ghanta R, Carrasquillo O, Martin P. Clin Gastroenterol Hepatol. 2011 Oct;9(10):834-41. Epub 2011 May 12.


  612. Risk Factors of Ascites after Hepatectomy for Patients with Hepatocellular Carcinoma and Hepatitis B Virus-Associated Cirrhosis
    Chen LP, Li C, Wang C, Wen TF, Yan LN, Li B. Hepatogastroenterology. 2011 Aug 10;59(113). doi: 10.5754/hge11399. [Epub ahead of print]


  613. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation
    Chen TM, Lin CC, Huang PT, Wen CF. J Gastroenterol Hepatol. 2011 Sep 13. doi: 10.1111/j.1440-1746.2011.06910.x. [Epub ahead of print]


  614. Conclusions: High baseline NLR was associated with worse OS for patients with early HCC; post-RFA NLR predicted not only OS, but also tumor recurrence.
    Hashimoto E, Tokushige K. Hepatol Res. 2011 Sep 15. doi: 10.1111/j.1872-034X.2011.00872.x. [Epub ahead of print]


  615. A clinicopathological model to predict bone metastasis in hepatocellular carcinoma
    Xiang ZL, Zeng ZC, Fan J, Wu WZ, He J, Zeng HY, Tang ZY. J Cancer Res Clin Oncol. 2011 Sep 14. [Epub ahead of print]


  616. MELD Exceptions and Rates of Waiting List Outcomes
    Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, Schnitzler MA, Gheorghian A, Salvalaggio PR, Segev DL. Am J Transplant. 2011 Sep 15. doi: 10.1111/j.1600-6143.2011.03735.x. [Epub ahead of print]


  617. Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C
    Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Am J Gastroenterol. 2011 Sep 20. doi: 10.1038/ajg.2011.312. [Epub ahead of print]


  618. Critical Appraisal of Clinical Practice Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma
    Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06891.x. [Epub ahead of print]


  619. Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma with Decompensated Cirrhosis
    Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N, Mizushima T, Higashi T, Tanimoto M. Oncology. 2011 Sep 9;81(1):39-44. [Epub ahead of print]


  620. Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice
    van de Putte DF, Blom R, van Soest H, Mundt M, Verveer C, Arends J, Knegt RE, Mauser-Bunschoten E, van Erpecum K. Ann Hepatol. 2011 Oct 1;10(4):469-76.


  621. Hepatocellular carcinoma: clinical and radiological findings in patients with chronic B viral hepatitis and chronic C viral hepatitis
    Kim KE, Park MS, Bentley-Hibbert S, Baek SE, Kim YC, Kim MJ, Kim KW, Auh YH. Abdom Imaging. 2011 Sep 11. [Epub ahead of print]


  622. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor: two case reports
    Takahara T, Nitta H, Hasegawa Y, Itou N, Takahashi M, Wakabayashi G. Transplant Proc. 2011 Sep;43(7):2800-5.


  623. Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma
    Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. J Clin Oncol. 2011 Sep 12. [Epub ahead of print]


  624. Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice
    van de Putte DF, Blom R, van Soest H, Mundt M, Verveer C, Arends J, Knegt RE, Mauser-Bunschoten E, van Erpecum K. Ann Hepatol. 2011 Oct 1;10(4):469-76.


  625. Hepatocellular carcinoma: clinical and radiological findings in patients with chronic B viral hepatitis and chronic C viral hepatitis
    Kim KE, Park MS, Bentley-Hibbert S, Baek SE, Kim YC, Kim MJ, Kim KW, Auh YH. Abdom Imaging. 2011 Sep 11. [Epub ahead of print]


  626. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor: two case reports
    Takahara T, Nitta H, Hasegawa Y, Itou N, Takahashi M, Wakabayashi G. Transplant Proc. 2011 Sep;43(7):2800-5.


  627. Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma
    Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. J Clin Oncol. 2011 Sep 12. [Epub ahead of print]


  628. Critical Appraisal of Clinical Practice Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma
    Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06891.x. [Epub ahead of print]


  629. Long-Term Outcomes After Resection Versus Transplantation for Hepatocellular Carcinoma Within UCSF Criteria
    Ho CM, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Ann Surg Oncol. 2011 Aug 31. [Epub ahead of print]


  630. Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma
    Massarweh NN, Park JO, Bruix J, Yeung RS, Etzioni RB, Symons RG, Baldwin LM, Flum DR. J Oncol Pract. 2011 May;7(3):155-60.


  631. The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
    Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, Poon RT. Oncologist. 2011 Sep 1. [Epub ahead of print]


  632. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
    Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Aliment Pharmacol Ther. 2011 Aug 24. doi: 10.1111/j.1365-2036.2011.04823.x. [Epub ahead of print]


  633. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria
    Takuma Y, Nouso K, Makino Y, Gotoh T, Toshikuni N, Morimoto Y, Shimomura H, Yamamoto H. J Gastroenterol Hepatol. 2011 Sep;26(9):1417-24. doi: 10.1111/j.1440-1746.2011.06775.x.


  634. Hepatoceclullar Carcinoma and Vitamin D- A review
    Chiang KC, Yeh CN, Chen MF, Chen TC. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06892.x. [Epub ahead of print]


  635. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis
    Akima T, Tamano M, Hiraishi H. Hepatol Res. 2011 Aug 24. doi: 10.1111/j.1872-034X.2011.00846.x. [Epub ahead of print]


  636. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma
    Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma


  637. Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C
    Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y. Cancer Epidemiol Biomarkers Prev. 2011 Aug 29. [Epub ahead of print]


  638. CONCLUSIONS: Higher plasma ADAMTS13 activity and antigen level was a risk of HCC development in chronic liver disease.Impact:Plasma ADAMTS13 as a potential marker of hepatic stellate cells may be useful in the prediction of hepatocarcinogenesis.
    Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06891.x. [Epub ahead of print]


  639. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial
    Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui H. Oncol Rep. 2011 Aug 24. doi: 10.3892/or.2011.1433. [Epub ahead of print]


  640. Highly sensitive lens culinaris agglutinin-reactive ?-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease
    Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, Mawatari SI, Saishoji A, Kure T, Ohno K, Toyokura E, Imanaka D, Moriuchi A, Uto H, Oketani M, Hashiguchi T, Tsubouchi H. Oncol Rep. 2011 Aug 19. doi: 10.3892/or.2011.1425. [Epub ahead of print]


  641. Hepatitis B virus and hepatocellular carcinoma at the miRNA level
    Zhang ZZ, Liu X, Wang DQ, Teng MK, Niu LW, Huang AL, Liang Z. World J Gastroenterol. 2011 Jul 28;17(28):3353-8.


  642. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma
    Huang L, Li J, Lau WY, Yan J, Zhou F, Liu C, Zhang X, Shen J, Wu M, Yan Y. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06888.x. [Epub ahead of print]


  643. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma
    Kudo M. Dig Dis. 2011;29(3):289-302. Epub 2011 Aug 9.


  644. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy
    Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, Morelli MC, Ravaioli M, Pinna AD. Liver Transpl. 2011 Aug 11. doi: 10.1002/lt.22397. [Epub ahead of print]


  645. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation
    Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y. J Gastroenterol. 2011 Aug 16. [Epub ahead of print]


  646. Liver Transplantation for Hepatocellular Carcinoma: Five Steps to Prevent Recurrence
    Toso C, Mentha G, Majno P. Am J Transplant. 2011 Aug 10. doi: 10.1111/j.1600-6143.2011.03689.x. [Epub ahead of print]


  647. Viral Load, Genotypes, and Mutants in Hepatitis B Virus-Related Hepatocellular Carcinoma: Special Emphasis on Patients with Early Hepatocellular Carcinoma
    Chu CM, Lin CC, Lin SM, Lin DY, Liaw YF. Dig Dis Sci. 2011 Aug 12. [Epub ahead of print]


  648. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient
    Nissen NN, Menon V, Bresee C, Tran TT, Annamalai A, Poordad F, Fair JH, Klein AS, Boland B, Colquhoun SD. HPB (Oxford). 2011 Sep;13(9):626-32. doi: 10.1111/j.1477-2574.2011.00342.x. Epub 2011 Jul 19.


  649. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma
    Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH. Eur J Cancer. 2011 Aug 9. [Epub ahead of print]


  650. Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C
    Nojiri S, Kusakabe A, Shinkai N, Matsuura K, Iio E, Miyaki T, Joh T. Cancer Manag Res. 2011;3:267-72. Epub 2011 Jul 28.


  651. Conventional versus Doxorubicin-eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma
    Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M, Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C. J Vasc Interv Radiol. 2011 Aug 15. [Epub ahead of print]


  652. Repeat treatment for recurrent hepatocellular carcinoma: is it validated?
    Kishi Y, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguchi T. Langenbecks Arch Surg. 2011 Aug 17. [Epub ahead of print]


  653. Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C
    Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ. J Clin Oncol. 2011 Aug 22. [Epub ahead of print]


  654. mTOR Inhibitor for the Treatment of Hepatocellular Carcinoma
    Kudo M. Dig Dis. 2011;29(3):310-5. Epub 2011 Aug 9.


  655. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults
    Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Häggström C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H. Int J Cancer. 2011 Jul 29. doi: 10.1002/ijc.26338. [Epub ahead of print]


  656. Management of patients with hepatocellular carcinoma and extrahepatic metastasis
    Lee HS. Dig Dis. 2011;29(3):333-8. Epub 2011 Aug 9.


  657. Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trials
    Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Med Sci Monit. 2011 Aug 1;17(8):RA169-176.


  658. Hepatocellular Carcinoma Screening Rates Vary by Etiology of Cirrhosis and Involvement of Gastrointestinal Sub-specialists
    Patwardhan V, Paul S, Corey KE, Mazhar SM, Richter JM, Thiim M, Chung RT. Dig Dis Sci. 2011 Jul 30. [Epub ahead of print]


  659. Radiofrequency ablation of high grade dysplastic nodules
    Cho YK, Chung JW, Kim Y, Cho HJ, Yang SH. Hepatology. 2011 Aug 1. doi: 10.1002/hep.24589. [Epub ahead of print]


  660. Radioembolization for hepatocellular carcinoma
    Sangro B, Iñarrairaegui M, Bilbao JI. J Hepatol. 2011 Aug 1. [Epub ahead of print]


  661. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone
    Kim HY, Park JW. Dig Dis. 2011;29(3):303-9. Epub 2011 Aug 9.


  662. Underweight patients show an increased rate of postoperative death after surgery for hepatocellular carcinoma
    Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. J Surg Oncol. 2011 Aug 3. doi: 10.1002/jso.22049. [Epub ahead of print]


  663. Level of Alpha-Fetoprotein Predicts Mortality among Patients with Hepatitis C-Related Hepatocellular Carcinoma
    Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Aug 3. [Epub ahead of print]


  664. Chronic inflammation and hepatocellular carcinoma
    Alison MR, Nicholson LJ, Lin WR. Recent Results Cancer Res. 2011;185:135-48.


  665. Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma
    Zheng S, Tansey WP, Hiebert SW, Zhao Z. BMC Med Genomics. 2011 Aug 8;4(1):62. [Epub ahead of print]


  666. Future treatment option for hepatocellular carcinoma: a focus on brivanib
    Kudo M. Dig Dis. 2011;29(3):316-20. Epub 2011 Aug 9.


  667. Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients
    Kanda T, Imazeki F, Mikami S, Kato K, Shimada N, Yonemitsu Y, Miyauchi T, Arai M, Fujiwara K, Tsubota A, Takada N, Nishino T, Takashi M, Sugiura N, Kimura M, Fukai K, Yokosuka O. Oncology. 2011 Aug 3;80(5-6):366-372. [Epub ahead of print]


  668. Long term survival in patients with hepatocellular carcinoma directly invading the gastrointestinal tract: Case reports and literature review
    Lin TL, Yap AQ, Wang JH, Chen CL, Iyer SG, Low JK, Lin CC, Li WF, Chen TY, Bora D, Lin CY, Wang CC. Surg Oncol. 2011 Aug 6. [Epub ahead of print]


  669. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma
    Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Hepatology. 2011 Jul 11. doi: 10.1002/hep.24551. [Epub ahead of print]


  670. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis
    Wang WM, Xu Y, Yang XR, Wang YH, Sun HX, Fan J. Hepatobiliary Pancreat Dis Int. 2011 Aug;10(4):346-55.


  671. Prospective evaluation of the management of hepatocellular carcinoma in the elderly
    Ozenne V, Bouattour M, Goutté N, Vullierme MP, Ripault MP, Castelnau C, Valla DC, Degos F, Farges O. Dig Liver Dis. 2011 Jul 26. [Epub ahead of print]


  672. Feasibility of conducting a randomised control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?
    Poustchi H, Farrell G, Strasser S, Lee A, McCaughan G, George J. Hepatology. 2011 Jul 28. doi: 10.1002/hep.24581. [Epub ahead of print]


  673. Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge
    Poon RT. Hepatology. 2011 Jul 25. doi: 10.1002/hep.24569. [Epub ahead of print]


  674. Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma
    Boulin M, Ciboulet A, Guiu B, Maillard E, Bonnetain F, Minello A, Gagnaire A, Lepage C, Krause D, Hillon P, Bedenne L, Cercueil JP, Chauffert B, Jouve JL. Dig Liver Dis. 2011 Jul 27. [Epub ahead of print]


  675. Summary of candidate selection and expanded criteria for liver transplantation for HCC: A review and consensus statement from the 2010 international consensus conference on liver transplantation for hepatocellular carcinoma
    Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon D, Freeman RB. Liver Transpl. 2011 Jul 11. doi: 10.1002/lt.22380. [Epub ahead of print]


  676. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis
    Wee A. Cytopathology. 2011 Jul 18. doi: 10.1111/j.1365-2303.2011.00882.x. [Epub ahead of print]


  677. Hepatitis C virus-related hepatocellular carcinoma and liver cirrhosis
    Pecic V, Stankovic-Djordjevic D, Nestorovic M, Radojkovic M, Marjanovic H, Ilic B, Milojkovic M. J BUON. 2011 Apr-Jun;16(2):277-81. Source Clinic for General Surgery, Clinical Center Nis, Nis, Serbia. acrepus@yahoo.com


  678. Comparison of staging systems of hepatocellular carcinoma
    Sirivatanauksorn Y, Tovikkai C. HPB Surg. 2011;2011:818217. Epub 2011 Jun 27. Sources HPB and Transplantation Unit, Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand


  679. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant
    Truesdale AE, Caldwell SH, Shah NL, Argo CK, Al-Osaimi AM, Schmitt TM, Northup PG. Transpl Int. 2011 Jul 21. doi: 10.1111/j.1432-2277.2011.01299.x. [Epub ahead of print]


  680. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis
    Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Int J Cancer. 2011 Jul 21. doi: 10.1002/ijc.26301. [Epub ahead of print]


  681. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma
    Tiong L, Maddern GJ. Br J Surg. 2011 Jul 15. doi: 10.1002/bjs.7669. [Epub ahead of print]


  682. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib
    Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, Lee JD, Choi HJ. Liver Int. 2011 May 3. doi: 10.1111/j.1478-3231.2011.02541.x. [Epub ahead of print]


  683. Imaging and early diagnosis of hepatocellular carcinoma
    Peck-Radosavljevic M. Minerva Gastroenterol Dietol. 2011 Sep;57(3):273-86.


  684. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience
    Semrad TJ, Gandara DR, Lara PN Jr. Ther Adv Med Oncol. 2011 Mar;3(2):95-100.


  685. M-TOR Inhibitors: What Role in Liver Transplantation?
    Kawahara T, Asthana S, Kneteman NM. J Hepatol. 2011 Jul 19. [Epub ahead of print]


  686. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC); An emerging field for advanced technologies
    Marquardt JU, Galle PR, Teufel A. J Hepatol. 2011 Jul 20. [Epub ahead of print]


  687. Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration
    Teufel A, Marquardt JU, Galle PR. J Hepatol. 2011 Jul 20. [Epub ahead of print]


  688. Liver cancer and non-hodgkin lymphoma in hepatitis C virus-infected patients: results from the danvir cohort study
    Omland LH, Jepsen P, Krarup H, Christensen PB, Weis N, Nielsen L, Obel N, Sørensen HT, Stuver SO; on behalf of the DANVIR cohort study. Int J Cancer. 2011 Jul 21. doi: 10.1002/ijc.26283. [Epub ahead of print]


  689. Hepatocellular carcinoma: molecular and genomic guideline for the clinician
    Frenette C, Gish RG. Clin Liver Dis. 2011 May;15(2):307-21.


  690. Radiofrequency Ablation versus Surgical Resection as Primary Treatment of Hepatocellular Carcinoma Meeting the Milan Criteria: A Systematic Review
    Cho YK, Rhim H, Noh S. J Gastroenterol Hepatol. 2011 Jun 16. doi: 10.1111/j.1440-1746.2011.06812.x. [Epub ahead of print]


  691. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma
    Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, Fan ST. Arch Surg. 2011 Jun;146(6):675-81.


  692. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma
    Siddique A, Kowdley KV. Clin Liver Dis. 2011 May;15(2):281-96.


  693. Liver transplant recipient survival benefit with living donation in the MELD allocation era
    Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE. Hepatology. 2011 Jun 17. doi: 10.1002/hep.24494. [Epub ahead of print]


  694. Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma
    Saif MW, Isufi I, Peccerillo J, Syrigos KN. Gastroenterol Res Pract. 2011;2011:616080. Epub 2011 May 30.


  695. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007
    Thein HH, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ. Viral Hepat. 2011 Jul;18(7):e232-e241. doi: 10.1111/j.1365-2893.2011.01440.x. Epub 2011 Feb 17.


  696. The global epidemiology of hepatocellular carcinoma: present and future
    McGlynn KA, London WT. Clin Liver Dis. 2011 May;15(2):223-43.


  697. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance
    Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, Di Marco V, Farinati F, Del Poggio P, Borzio F, Borzio M, Caturelli E, Di Nolfo MA, Frigerio M, Brancaccio G, Gaeta GB. Dig Liver Dis. 2011 Jun 18. [Epub ahead of print]


  698. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study
    Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; on behalf of the Italian Liver Cancer group. Lancet Oncol. 2011 Jun 16. [Epub ahead of print]


  699. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy
    Gonzalez SA, Keeffe EB. Clin Liver Dis. 2011 May;15(2):297-306.


  700. The effect of changes of model for end-stage liver disease score during waiting time on post-liver transplant mortality
    Al-Freah MA, Gane EJ, Livingstone V, McCall J, Munn S. Hepatol Int. 2011 Jun 30. [Epub ahead of print]


  701. Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest
    Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. J Gastrointest Surg. 2011 Jul 2. [Epub ahead of print]


  702. Criteria for liver transplantation for HCC: What should the limits be?
    Silva MF, Sherman M. J Hepatol. 2011 Jun 27. [Epub ahead of print]


  703. Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study
    Kim JH, Yim HJ, Lee KG, Kim SY, Jung ES, Jung YK, Kim JH, Seo YS, Yeon JE, Lee HS, Um SH, Byun KS, Ryu HS. Hepatol Int. 2011 Jul 5. [Epub ahead of print]


  704. Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
    Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Gastroenterology. 2011 Jul 1. [Epub ahead of print]


  705. Viruses and cancers: possible role of hepatitis C virus
    Ferri C, La Civita L, Zignego AL, Pasero G. Eur J Clin Invest. 1997 Sep;27(9):711-8.


  706. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean?
    Shaw JJ, Shah SA. Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):365-70.


  707. Treatment strategy for early hepatocellular carcinomas: Comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection
    Tashiro H, Aikata H, Waki K, Amano H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Chayama K, Asahara T, Ohdan H. J Surg Oncol. 2011 Jul 1;104(1):3-9. doi: 10.1002/jso.21745.


  708. Contrast enhanced ultrasound for the characterization of hepatocellular carcinoma
    Martie A, Sporea I, Popescu A, Sirli R, D?nil? M, Serban C, Ardelean M, Bota S, Sendroiu M, Chisevescu D. Med Ultrason. 2011 Jun;13(2):108-13.


  709. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group
    Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, Molassiotis A. Eur J Oncol Nurs. 2011 Jun 2. [Epub ahead of print]


  710. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria
    Fan ST, Poon RT, Yeung C, Lam CM, Lo CM, Yuen WK, Ng KK, Liu CL, Chan SC. Br J Surg. 2011 Jun 7. doi: 10.1002/bjs.7583. [Epub ahead of print]


  711. Risk Factors Influencing Postoperative Outcomes of Major Hepatic Resection of Hepatocellular Carcinoma for Patients with Underlying Liver Diseases
    Yang T, Zhang J, Lu JH, Yang GS, Wu MC, Yu WF. World J Surg. 2011 Jun 9. [Epub ahead of print]


  712. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction
    Hsin IF, Hsu CY, Huang HC, Huang YH, Lin HC, Lee RC, Chiang JH, Lee FY, Huo TI, Lee SD. J Clin Gastroenterol. 2011 Jul;45(6):556-62.


  713. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma
    Williet N, Dubreuil O, Boussaha T, Trouilloud I, Landi B, Housset M, Botti M, Rougier P, Belghiti J, Taieb J. World J Gastroenterol. 2011 May 7;17(17):2255-8.


  714. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
    Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Eur J Cancer. 2011 Jun 9. [Epub ahead of print]


  715. Current concepts in transarterial chemoembolization of hepatocellular carcinoma
    Huppert P. Abdom Imaging. 2011 Jun 15. [Epub ahead of print]


  716. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis
    Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S. Gastrointest Cancer Res. 2011 Mar;4(2):40-4.


  717. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection
    Hsu A, Lai CL, Yuen MF. Curr Hepat Rep. 2011 Jun;10(2):106-111. Epub 2011 Feb 19.


  718. Survival after (90) Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation
    Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S; on behalf of European Network on Radioembolization with yttrium-90 resin microspheres (ENRY). Hepatology. 2011 May 26. doi: 10.1002/hep.24451. [Epub ahead of print]


  719. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers
    Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'errico-Grigioni A, Golfieri R, Pinna AD. Transplantation. 2011 Jun 15;91(11):1279-85.


  720. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or hepatitis C
    Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, Dore GJ. J Gastroenterol Hepatol. 2011 May 26. doi: 10.1111/j.1440-1746.2011.06785.x. [Epub ahead of print]


  721. Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients
    Ataide EC, Boin IF, Almeida JR, Sevá-Pereira T, Stucchi RS, Cardoso AR, Caruy CA, Escanhoela CA. Transplant Proc. 2011 May;43(4):1362-4.


  722. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
    Vernon G, Baranova A, Younossi ZM. Aliment Pharmacol Ther. 2011 May 30. doi: 10.1111/j.1365-2036.2011.04724.x. [Epub ahead of print]


  723. The impact of milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the hungarian liver transplant program
    Nemes B, Gelley F, Piros L, Zádori G, Görög D, Fehérvári I, Kóbori L, Sárváry E, Nagy P, Kiss A, Doros A. Transplant Proc. 2011 May;43(4):1272-4.


  724. T oSystematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria
    Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. Br J Surg. 2011 May 27. doi: 10.1002/bjs.7561. [Epub ahead of print]


  725. Sorafenib enhances pemetrexed cytotoxicity through an autophagy -dependent mechanism in cancer cells
    Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Cancer Res. 2011 May 27. [Epub ahead of print]


  726. Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension
    Elia C, Venon WD, Stradella D, Martini S, Brunello F, Marzano A, Saracco G, Rizzetto M. Eur J Gastroenterol Hepatol. 2011 May 4. [Epub ahead of print]


  727. Super-selection of a Subgroup of Hepatocellular Carcinoma Patients at Minimal Risk of Recurrence for Liver Transplantation
    Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Yu YD, Park PJ, Choi YI, Kim KW, Lim YS, Lee HC, Yu ES, Lee SG. J Gastrointest Surg. 2011 Jun;15(6):971-81. Epub 2011 Mar 29.


  728. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma
    Tsai YJ, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee SD. Hepatol Int. 2011 Apr 30. [Epub ahead of print]


  729. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index
    Kao WY, Chiou YY, Hung HH, Chou YH, Su CW, Wu JC, Huo TI, Huang YH, Lin HC, Lee SD. Eur J Gastroenterol Hepatol. 2011 Jun;23(6):528-36.


  730. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta-analysis of cohort studies
    Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L. Int J Cancer. 2011 May 4. doi: 10.1002/ijc.26165. [Epub ahead of print]


  731. Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention
    Giacomin A, Cazzagon N, Sergio A, Vanin V, Farinati F. Eur J Cancer Prev. 2011 May 2. [Epub ahead of print]


  732. Metabolic syndrome increases the risk of primary liver cancer in the United States: A population-based case-control study.
    Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Hepatology. 2011 Apr 29. doi: 10.1002/hep.24397. [Epub ahead of print]


  733. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up
    Guan YS, Liu Y, He Q, Li X, Yang L, Hu Y, La Z. World J Gastroenterol. 2011 Apr 28;17(16):2143-9.


  734. Safety of hepatic resection in overweight and obese patients with cirrhosis
    Cucchetti A, Cescon M, Ercolani G, Di Gioia P, Peri E, Pinna AD. Br J Surg. 2011 Apr 20. doi: 10.1002/bjs.7516. [Epub ahead of print]


  735. Development of hepatocellular carcinomas in patients with absence of tumors on a prior ultrasound examination
    Kim KA, Kim MJ, Choi JY, Chung YE. Eur J Radiol. 2011 Apr 21. [Epub ahead of print]


  736. Surgical Outcomes for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
    Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, Hatakeyama K.SourceJ Gastrointest Surg. 2011 Apr 22. [Epub ahead of print]


  737. Fibrosis in chronic viral hepatitis
    Calvaruso V, Craxì A. Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):219-30.


  738. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis
    Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD. Liver Transpl. 2011 May;17(5):556-66. doi: 10.1002/lt.22273.


  739. Immunosuppression and hepatocellular carcinoma
    Hj S, F M, A S, Jf T. Liver Transpl. 2011 Apr 19. doi: 10.1002/lt.22318. [Epub ahead of print]


  740. Hepatocellular carcinoma and liver transplantation
    Washburn K, Halff G. Curr Opin Organ Transplant. 2011 Apr 17. [Epub ahead of print]


  741. Effect of Oral Supplementation with Branched-chain Amino Acid (BCAA) during Radiotherapy in Patients with Hepatocellular Carcinoma: A Double-Blind Randomized Study
    Lee IJ, Seong J, Bae JI, You SH, Rhee Y, Lee JH. Cancer Res Treat. 2011 Mar;43(1):24-31. Epub 2011 Mar 31. Cancer Res Treat. 2011 Mar;43(1):24-31. Epub 2011 Mar 31


  742. Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma
    Chua TC, Morris DL. Surg Oncol. 2011 Mar 10. [Epub ahead of print]


  743. Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era
    Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y. World J Surg. 2011 May;35(5):1072-84.


  744. Superior long-term outcomes after surgery in child-pugh class a patients with single small hepatocellular carcinoma compared to radiofrequency ablation
    Yun WK, Choi MS, Choi D, Rhim HC, Joh JW, Kim KH, Jang TH, Lee JH, Koh KC, Paik SW, Yoo BC. Hepatol Int. 2010 Dec 25. [Epub ahead of print]


  745. Transarterial chemoembolization as salvage therapy after unsuccessful hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma
    Fukumori K, Yano Y, Ando E, Sumie S, Kuwaki K, Yamashita F, Tanaka M, Sata M. Mol Med Report. 2008 Jul-Aug;1(4):521-4.


  746. FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria
    Sun H, Teng M, Liu J, Jin D, Wu J, Yan D, Fan J, Qin X, Tang H, Peng Z. Cancer Lett. 2011 Apr 9. [Epub ahead of print]


  747. Cancer risk in chronic hepatitis B: Do genome-wide association studies hit the mark?
    Casper M, Grünhage F, Lammert F. Hepatology. 2011 Apr;53(4):1390-2. doi: 10.1002/hep.24241.


  748. Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma
    Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, Tsuge M, Chayama K. Hepatology. 2011 Apr;53(4):1237-45. doi: 10.1002/hep.24207.


  749. Expression level of glutamine synthetase is increased in hepatocellular carcinoma and liver tissue with cirrhosis and chronic hepatitis B
    Long J, Wang H, Lang Z, Wang T, Long M, Wang B. Hepatol Int. 2010 Dec 28. [Epub ahead of print]


  750. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
    Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N, Toriyabe T, Shinozaki Y, Ooka Y, Mikata R, Chiba T, Okabe S, Imazeki F, Yoshikawa M, Yokosuka O. Hepatol Int. 2011 Jan 22. [Epub ahead of print]


  751. Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis
    Enomoto S, Tamai H, Shingaki N, Mori Y, Moribata K, Shiraki T, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Hepatol Int. 2011 Jan 9. [Epub ahead of print]


  752. Treatment options in hepatocellular carcinoma today
    Livraghi T, Mäkisalo H, Line PD. Scand J Surg. 2011;100(1):22-9.


  753. Therapeutic options for intermediate-advanced hepatocellular carcinoma
    Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. World J Gastroenterol. 2011 Apr 7;17(13):1685-9.


  754. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation
    Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S, Koike K, Omata M. Hepatol Int. 2011 Jan 25. [Epub ahead of print]


  755. MR-arterioportography: A new technical approach for detection of liver lesions
    Rennert J, Jung EM, Schreyer AG, Hoffstetter P, Heiss P, Feuerbach S, Zorger N. World J Gastroenterol. 2011 Apr 7;17(13):1739-45.


  756. Gene profiling of early and advanced liver disease in chronic hepatitis C patients
    Khalid SS, Hamid S, Siddiqui AA, Qureshi A, Qureshi N. Hepatol Int. 2011 Jan 22. [Epub ahead of print]


  757. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience
    Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Ann Surg. 2011 Apr;253(4):745-58.


  758. Prognosis of patients with hepatocellular carcinoma after hepatic resection: Are elderly patients suitable for surgery?
    Nanashima A, Abo T, Nonaka T, Fukuoka H, Hidaka S, Takeshita H, Ichikawa T, Sawai T, Yasutake T, Nakao K, Nagayasu T. J Surg Oncol. 2011 Apr 1. doi: 10.1002/jso.21932. [Epub ahead of print]


  759. A Functional Polymorphism in the Epidermal Growth Factor Gene is Associated with Risk for Hepatocellular Carcinoma
    Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group. Gastroenterology. 2011 Mar 24. [Epub ahead of print]


  760. Progression of liver cirrhosis to HCC: an application of hidden Markov model
    Bartolomeo N, Trerotoli P, Serio G. BMC Med Res Methodol. 2011 Apr 4;11(1):38. [Epub ahead of print]


  761. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection
    Yamashita T, Honda M, Kaneko S. J Gastroenterol Hepatol. 2011 Mar 28. doi: 10.1111/j.1440-1746.2011.06723.x. [Epub ahead of print]


  762. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK. Cancer Chemother Pharmacol. 2011 Mar 29. [Epub ahead of print]


  763. Barriers to Providing Health Services for HIV/AIDS, Hepatitis C Virus Infection and Sexually Transmitted Infections in Substance Abuse Treatment Programs in the United States
    Bini Deceased EJ, Kritz S, Brown LS Jr, Robinson J, Alderson D, Rotrosen J. J Addict Dis. 2011 Apr;30(2):98-109.


  764. Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C
    Sato S, Genda T, Hirano K, Tsuzura H, Kanemitsu Y, Narita Y, Kikuchi T, Ijima K, Ichida T. Hepatol Int. 2011 Apr 2. [Epub ahead of print]


  765. Racial differences in hepatitis C treatment eligibility
    Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; on behalf of the IDEAL Study Team. Hepatology. 2011 Apr 12. doi: 10.1002/hep.24358. [Epub ahead of print]


  766. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma
    Jin B, Wang D, Lewandowski RJ, Riaz A, Ryu RK, Sato KT, Larson AC, Salem R, Omary RA. AJR Am J Roentgenol. 2011 Apr;196(4):919-28.


  767. Surveillance of small intestinal abnormalities in patients with hepatocellular carcinoma: a prospective capsule endoscopy study
    Yamada A, Watabe H, Obi S, Sugimoto T, Kondo S, Ohta M, Togo G, Ogura K, Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Koike K, Omata M. Dig Endosc. 2011 Apr;23(2):124-9. doi: 10.1111/j.1443-1661.2010.01050.x. Epub 2010 Dec 7.


  768. Strategies for HCC therapy and diagnostics - lessons learned from high throughput and profiling approaches
    Breuhahn K, Gores G, Schirmacher P. Hepatology. 2011 Mar 23. doi: 10.1002/hep.24313. [Epub ahead of print]


  769. Radiofrequency ablation for hepatocellular carcinoma: use of low versus maximal radiofrequency power
    Macatula TC, Lin CC, Lin CJ, Chen WT, Lin SM. Br J Radiol. 2011 Mar 22. [Epub ahead of print]


  770. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: comparison of effects of thermal protection and therapeutic efficacy
    Kang TW, Rhim H, Lee MW, Kim YS, Choi D, Lee WJ, Lim HK. AJR Am J Roentgenol. 2011 Apr;196(4):907-13.


  771. Molecular predictors of response to antiangiogenesis therapies
    Gerger A, Labonte M, Lenz HJ. Cancer J. 2011 Mar-Apr;17(2):134-41.


  772. Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
    Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH. Mol Ther. 2011 Mar 22. [Epub ahead of print]


  773. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK. Cancer Chemother Pharmacol. 2011 Mar 29. [Epub ahead of print]


  774. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection
    Yamashita T, Honda M, Kaneko S. J Gastroenterol Hepatol. 2011 Mar 28. doi: 10.1111/j.1440-1746.2011.06723.x. [Epub ahead of print]


  775. Progression of liver cirrhosis to HCC: an application of hidden Markov model
    Bartolomeo N, Trerotoli P, Serio G. BMC Med Res Methodol. 2011 Apr 4;11(1):38. [Epub ahead of print]


  776. Sorafenib-induced premalignant and malignant skin lesions
    Williams VL, Cohen PR, Stewart DJ. Int J Dermatol. 2011 Apr;50(4):396-402. doi: 10.1111/j.1365-4632.2010.04822.x.


  777. Radiofrequency ablation of hepatocellular carcinoma
    Livraghi T. Surg Oncol Clin N Am. 2011 Apr;20(2):281-99.


  778. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management
    Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Radiology. 2011 Mar;258(3):673-93


  779. Sorafenib-associated hand-foot syndrome in Japanese patients
    Iijima M, Fukino K, Adachi M, Tsukamoto T, Murai M, Naito S, Minami H, Furuse J, Akaza H. J Dermatol. 2011 Mar;38(3):261-266


  780. Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma
    Kaibori M, Ishizaki M, Matsui K, Kitade H, Matsui Y, Kwon AH. J Gastroenterol Hepatol. 2011 Mar;26(3):536-43.


  781. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy
    Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. J Gastroenterol. 2011 Mar 4. [Epub ahead of print]


  782. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]


  783. Computed Tomography Findings of Sorafenib-treated Hepatic Tumors in Patients with Advanced Hepatocellular Carcinoma
    Kim MJ, Choi JI, Lee JS, Park JW. J Gastroenterol Hepatol. 2011 Mar 3. [Epub ahead of print]


  784. Repeated liver resection for recurrent hepatocellular carcinoma
    Faber W, Seehofer D, Neuhaus P, Stockmann M, Denecke T, Kalmuk S, Warnick P, Bahra M. J Gastroenterol Hepatol. 2011 Mar 16. doi: 10.1111/j.1440-1746.2011.06721.x. [Epub ahead of print]


  785. Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors
    Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD. Br J Clin Pharmacol. 2011 Mar 11. doi: 10.1111/j.1365-2125.2011.03963.x. [Epub ahead of print]


  786. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
    Oliveri RS, Wetterslev J, Gluud C. Cochrane Database Syst Rev. 2011 Mar 16;3:CD004787.


  787. Hepatocellular Carcinoma: Prevention and Therapy
    Sohal DP, Sun W. Curr Oncol Rep. 2011 Mar 17. [Epub ahead of print]


  788. Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer
    Tang Y, Zeng X, He F, Liao Y, Qian N, Toi M. Med Oncol. 2011 Mar 17. [Epub ahead of print]


  789. The Management of Hospitalized Patients with Cirrhosis: The Mount Sinai Experience and a Guide for Hospitalists
    Perumalswami PV, Schiano TD. Dig Dis Sci. 2011 Mar 18. [Epub ahead of print]


  790. Targeted Therapies for Hepatocellular Carcinoma
    Villanueva A, Llovet JM. Gastroenterology. 2011 Mar 12. [Epub ahead of print]


  791. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients
    Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. World J Gastroenterol. 2011 Feb 21;17(7):914-21.


  792. Sorafenib for advanced hepatocellular carcinoma: a systematic review
    Ling Lin Z, Li M, Jin-Hui T, Ke Hu Y. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Feb 10;33(1):51-7.


  793. Hepatic Resection for Transplantable Hepatocellular Carcinoma for Patients Within Milan and UCSF Criteria
    Chua TC, Saxena A, Chu F, Morris DL. Am J Clin Oncol. 2011 Feb 17. [Epub ahead of print]


  794. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma
    Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; The Japan NASH Study Group, The Ministry of Health, Labour and Welfare of Japan. Clin Gastroenterol Hepatol. 2011 Feb 11. [Epub ahead of print]


  795. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
    Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, Cheng AL, Shih TT. J Hepatol. 2011 Feb 18. [Epub ahead of print]


  796. Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience
    Fan ST, Lo CM, Poon RT, Yeung C, Liu CL, Yuen WK, Lam CM, Ng KK, Chan SC. Ann Surg. 2011 Feb 17. [Epub ahead of print]


  797. A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma
    Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX. Oncologist. 2011 Feb 24. [Epub


  798. Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma
    Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas MB, Harris R, Baudelet C, Walters I, Raoul J. Clin Cancer Res. 2011 Feb 24. [Epub ahead of print]


  799. Prognostic Factors and 10-Year Survival in Patients with Hepatocellular Carcinoma After Curative Hepatectomy
    Kim SH, Choi SB, Lee JG, Kim SU, Park MS, Kim DY, Choi JS, Kim KS. J Gastrointest Surg. 2011 Feb 19. [Epub ahead of print]


  800. Efficacy of selective transarterial chemoembolization in obtaining tumor necrosis in small (<5 cm) hepatocellular carcinomas
    Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, Ravaioli M, D'Errico-Grigioni A, Pinna AD, Bolondi L. Hepatology. 2011 Feb 23.[Epub ahead of print]


  801. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies
    Tanaka S, Arii S. J Gastroenterol. 2011 Feb 25. [Epub ahead of print]


  802. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib
    Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S, Sogni P, Pol S, Blanchet B, Legmann P, Goldwasser F. PLoS One. 2011 Feb 14


  803. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways
    Schattenberg JM, Schuchmann M, Galle PR. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:213-9.


  804. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies
    Lord R, Suddle A, Ross PJ. Int J Clin Pract. 2011 Feb;65(2):182-8.


  805. Building a Comprehensive Genomic Program for Hepatocellular Carcinoma
    Harring TR, Guiteau JJ, Nguyen NT, Cotton RT, Gingras MC, Wheeler DA, O'Mahony CA, Gibbs RA, Brunicardi FC, Goss JA. World J Surg. 2011 Jan 12. [Epub ahead of print]


  806. A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery
    Tsai HW, Lin YJ, Lin PW, Wu HC, Hsu KH, Yen CJ, Chan SH, Huang W, Su IJ. Cancer. 2011 Jan 10. [Epub ahead of print]


  807. Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B
    Yeung P, Wong DK, Lai CL, Fung J, Seto WK, Yuen MF. J Infect Dis. 2011 Jan 12. [Epub ahead of print]


  808. Comparison of Differences and Determinants Between Presence and Absence of Sleep Disturbance in Hepatocellular Carcinoma Patients
    Chu TL, Yu WP, Chen SC, Peng HL, Wu MJ. Cancer Nurs. 2011 Jan 15. [Epub ahead of print]


  809. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States
    Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Ann Intern Med. 2011 Jan 18;154(2):85-93.


  810. Sorafenib and radiotherapy association for hepatocellular carcinoma
    Girard N, Mornex F. Cancer Radiother. 2011 Jan 14. [Epub ahead of print]


  811. Evaluation of Absolute Serum {alpha}-Fetoprotein Levels in Liver Transplant for Hepatocellular Cancer
    Mailey B, Artinyan A, Khalili J, Denitz J, Sanchez-Luege N, Sun CL, Bhatia S, Nissen N, Colquhoun SD, Kim J. Arch Surg. 2011 Jan;146(1):26-33.


  812. Assessment of Chronic Hepatitis B - the importance of HBV DNA testing
    Croagh CM, Bell SJ, Locarnini S, Desmond PV. Intern Med J. 2011 Jan 17. [Epub ahead of print]


  813. Criteria for liver transplantation for hepatocellular carcinoma: what is an acceptable outcome?
    Belghiti J, Durand F. Liver Int. 2011 Jan;31 Suppl 1:161-3


  814. Clinical Significance of Alpha-Fetoprotein mRNA in Peripheral Blood in Liver Resection for Hepatocellular Carcinoma
    Marubashi S, Nagano H, Wada H, Kobayashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Ann Surg Oncol. 2011 Feb 8. [Epub ahead of print]


  815. Hepatocellular Carcinoma in Older Adults: Clinical Features, Treatments, and Survival
    Lee SH, Choi HC, Jeong SH, Lee KH, Chung JI, Park YS, Hwang JH, Kim JW, Kim N, Lee DH, Choi HC, Yoon CJ, Kang SG. J Am Geriatr Soc. 2011 Jan 28. [Epub ahead of print]


  816. Advanced hepatocellular carcinoma. Review of targeted molecular drugs
    Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M, Terrabuio D, Kondo M, Gampel O, Polletti P. Ann Hepatol. 2011 Jan 3;10(1):21-7.


  817. Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis
    Schütte K, Zimmermann L, Bornschein J, Csepregi A, Rühl R, Ricke J, Malfertheiner P. Digestion. 2011 Feb 1;83(4):275-282. [Epub ahead of print]


  818. Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population
    Li Y, Chang SC, Goldstein BY, Scheider WL, Cai L, You NC, Tarleton HP, Ding B, Zhao J, Wu M, Jiang Q, Yu S, Rao J, Lu QY, Zhang ZF, Mu L. Cancer Epidemiol. 2011 Feb 9. [Epub ahead of print]


  819. Hepatocellular cancer in the non-cirrhotic liver
    Alkofer B, Lepennec V, Chiche L. J Visc Surg. 2011 Feb 7. [Epub ahead of print]


  820. Molecular Pathogenesis of Hepatocellular Carcinoma
    Cornellà H, Alsinet C, Villanueva A. Alcohol Clin Exp Res. 2011 Feb 8. [Epub ahead of print]


  821. Hepatitis B Virus Core Protein Variations Differ in Tumor and Adjacent Nontumor Tissues from Patients with Hepatocellular Carcinoma
    Zhu Y, Jin Y, Cai X, Bai X, Chen M, Chen T, Wang J, Qian G, Gu J, Li J, Tu H. Intervirology. 2011 Feb 16. [Epub ahead of print]


  822. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma
    Guan YS, He Q. Expert Opin Pharmacother. 2011 Feb;12(2):303-13.


  823. HBV-related HCC, clinical issues and therapy
    Iavarone M, Colombo M. Dig Liver Dis. 2011 Jan;43 Suppl 1:S32-9


  824. Recent advances of radiofrequency ablation for early hepatocellular carcinoma
    Izumi N. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:115-22.


  825. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?
    Yoo DJ, Kim KM, Jin YJ, Shim JH, Ko GY, Yoon HK, Sung KB, Lee JL, Kang YK, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. J Gastroenterol Hepatol. 2011 Jan;26(1):145-54..


  826. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience
    Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A. Transplant Proc. 2010 Dec;42(10):4582-4.


  827. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy
    Saab S, McTigue M, Finn RS, Busuttil RW. Exp Clin Transplant. 2010 Dec;8(4):307-13.


  828. PI-103 and Sorafenib Inhibit Hepatocellular Carcinoma Cell Proliferation by Blocking Ras/Raf/MAPK and PI3K/AKT/mTOR Pathways
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM. Anticancer Res. 2010 Dec;30(12):4951-8.


  829. Established and emerging therapies for hepatocellular carcinoma
    Cicinnati VR, Sotiropoulos GC, Beckebaum S. Minerva Med. 2010 Dec;101(6):405-18.


  830. A Comparison of Prognosis between Patients with Hepatitis B and C Virus-related Hepatocellular Carcinoma Undergoing Resection Surgery
    Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. World J Surg. 2011 Jan 5. [Epub ahead of print]


  831. Understanding Surgical Decision Making in Early Hepatocellular Carcinoma
    Nathan H, Bridges JF, Schulick RD, Cameron AM, Hirose K, Edil BH, Wolfgang CL, Segev DL, Choti MA, Pawlik TM. J Clin Oncol. 2011 Jan 4. [Epub ahead of print]


  832. Hepatocellular carcinoma: the place of new medical therapies
    Peck-Radosavljevic M. Therap Adv Gastroenterol. 2010 Jul;3(4):259-67.


  833. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma
    Kang JY, Choi MS, Kim SJ, Kil JS, Lee JH, Koh KC, Paik SW, Yoo BC. Korean J Hepatol. 2010 Dec;16():383-8.


  834. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma
    Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. Int J Clin Oncol. 2010 Dec 9. [Epub ahead of print]


  835. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm
    Sulkes A. Isr Med Assoc J. 2010 Oct;12(10):628-32.


  836. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation
    Dubay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID, Grant DR, Greig PD. HPB (Oxford). 2011 Jan;13(1):24-32. Epub 2010 Nov 8.


  837. Sorafenib Modulates the Gene Expression of Multi-drug Resistance Mediating ATP-Binding Cassette Proteins in Experimental Hepatocellular Carcinoma
    Hoffmann K, Franz C, Xiao Z, Mohr E, Serba S, Büchler MW, Schemmer P. Anticancer Res. 2010 Nov;30(11):4503-8


  838. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation
    Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, Liu C, Qiu YH, Feng FL, Wang JH, Yan PN, Zhang BH, Wu MC, Luo XJ, Jiang XQ. Acta Pharmacol Sin. 2010 Dec;31(12):1643-8. Epub 2010 Nov 22.


  839. Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
    Xu LT, Chen Z, Lin JH, Zhou ZH, Chen H, Meng ZQ, Liu LM. Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):703-705.


  840. Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma
    Zhang L, Ren ZG, Gan YH, Wang YH, Zhang BH, Chen Y, Xie XY, Ge NL, Ye SL. Zhonghua Zhong Liu Za Zhi. 2010 Aug;32(8):630-3.


  841. Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program
    Chen WT, Fernandes ML, Lin CC, Lin SM. J Surg Oncol. 2010 Dec 7. [Epub ahead of print]


  842. Hepatocellular carcinoma treated with transarterial chemoembolization: Dynamic perfusion-CT in the assessment of residual tumor
    Ippolito D, Bonaffini PA, Ratti L, Antolini L, Corso R, Fazio F, Sironi S. World J Gastroenterol. 2010 Dec 21;16(47):5993-6000.


  843. Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib
    Spira D, Fenchel M, Lauer UM, Claussen CD, Gregor M, Bitzer M, Horger M. Acad Radiol. 2010 Oct 5. [Epub ahead of print]


  844. Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib
    Frenette CT, Frederick RT, Gish RG. J Clin Gastroenterol. 2010 Oct 6. [Epub ahead of print]


  845. Treatment of hepatitis C infections with interferon: a historical perspective
    Friedman RM, Contente S. Hepat Res Treat. 2010.Epub 2010 Sep 6.


  846. Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans
    Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. J Immigr Minor Health. 2010 Oct 2. [Epub ahead of print]


  847. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
    Scartozzi M, Svegliati Baroni G, Faloppi L, Di Pietro Paolo M, Pierantoni C, Candelari R, Berardi R, Antognoli S, Mincarelli C, Risaliti A, Marmorale C, Antico E, Benedetti A, Cascinu S. J Exp Clin Cancer Res. 2010 Dec 15;29(1):164. [Epub ahead of print]


  848. Hepatocellular carcinoma in thalassemia: A critical review
    Mancuso A. World J Hepatol. 2010 May 27;2(5):171-4.


  849. Liver Cancer Working Group report
    Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i19-27.


  850. Latest developments in targeted therapy for hepatocellular carcinoma
    Montella L, Addeo R, Caraglia M, Del Prete S. Expert Rev Anticancer Ther. 2010 Oct;10(10):1635-46.


  851. Underutilization of therapy for hepatocellular carcinoma in the medicare population
    Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. Cancer. 2010 Oct 13. [Epub ahead of print]


  852. Developing better treatments in hepatocellular carcinoma
    Duffy A, Greten T. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):551-60.


  853. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy
    Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Hepatol Res. 2010 Sep;40(9):870-7.


  854. Comparative Analysis of Outcome in Patients With Hepatocellular Carcinoma Exceeding the Milan Criteria Treated With Liver Transplantation Versus Partial Hepatectomy
    Canter RJ, Patel SA, Kennedy T, D?angelica MI, Jarnagin WR, Fong Y, Blumgart LH, Freeman RB, Dematteo RP, Abt PL. Am J Clin Oncol. 2010 Oct 8. [Epub ahead of print]


  855. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Kawamura Y, Arase Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H. Am J Med. 2010 Oct;123(10):951-956.e1.


  856. Surveillance for Hepatocellular Carcinoma: Development and Validation of an Algorithm to Classify Tests in Administrative and Laboratory Data
    Richardson P, Henderson L, Davila JA, Kramer JR, Fitton CP, Chen GJ, El-Serag HB. Dig Dis Sci. 2010 Sep 16. [Epub ahead of print]


  857. Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: Long-term results
    Peng ZW, Zhang YJ, Chen MS, Lin XJ, Liang HH, Shi M. Eur J Surg Oncol. 2010 Sep 14. [Epub ahead of print]


  858. Sorafenib in hepatocellular carcinoma
    Josephs DH, Ross PJ. Br J Hosp Med (Lond). 2010 Aug;71(8):451-6.


  859. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma
    Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, Li N, Ding HG. World J Gastroenterol. 2010 Sep 21;16(35):4410-5.


  860. Effects of Pegylated Interferon α2b on Metastasis of Hepatocellular Carcinoma
    Arakawa Y, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T. J Surg Res. 2010 Aug 6. [Epub ahead of print]


  861. Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study
    Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ, Chen CJ. J Clin Oncol. 2010 Sep 20. [Epub ahead of print]


  862. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation
    Iavarone M, Sangiovanni A, Forzenigo LV, Massironi S, Fraquelli M, Aghemo A, Ronchi G, Biondetti P, Roncalli M, Colombo M. Hepatology. 2010 Aug 19. [Epub ahead of print]


  863. High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients.
    Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, Ma HQ, Chen YB, Xia JC. World J Gastroenterol. 2010 Sep 28;16(36):4611-4615.


  864. Hepatitis B Genotype C Correlated with Poor Surgical Outcomes for Hepatocellular Carcinoma
    Liang TJ, Mok KT, Liu SI, Huang SF, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC, Wang BW. J Am Coll Surg. 2010 Sep 17. [Epub ahead of print]


  865. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms
    Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, Tiollais P. Pathol Biol (Paris). 2010 Jul 26. [Epub ahead of print]


  866. Identification of Novel Methylation Markers in Hepatocellular Carcinoma using a Methylation Array
    Shin SH, Kim BH, Jang JJ, Suh KS, Kang GH. J Korean Med Sci. 2010 Aug;25(8):1152-9. Epub 2010 Jul 20.


  867. Macrophage migration inhibitory factor plays a pivotal role in hepatocellular carcinoma and may be a noninvasive imaging target
    Han Y, Zhang C. Med Hypotheses. 2010 Jul 31. [Epub ahead of print]


  868. Non-viral causes of hepatocellular carcinoma
    Blonski W, Kotlyar DS, Forde KA. World J Gastroenterol. 2010 Aug 7;16(29):3603-15.


  869. Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study
    Hull D, Armstrong C. Int J Palliat Nurs. 2010 May;16(5):249-54.


  870. Pathology of hepatocellular carcinoma
    Mori W, Machinami R, Tanaka K. Pathol Res Pract. 1980;169(1):4-20.


  871. Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
    Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. J Clin Oncol. 2010 Aug 2. [Epub ahead of print]


  872. AASLD PRACTICE GUIDELINE: Management of Hepatocellular Carcinoma: An Update
    Bruix J and Sherman M. Hepatology July 2010;000 (000:;1-35)


  873. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy
    Kudo M. J Gastroenterol Hepatol. 2010 Mar;25(3):439-52.


  874. Antibiotic prophylaxis in transcatheter treatment of hepatocellular carcinoma: an open randomized prospective study of oral versus intravenous administration
    Ebisutani C, Sato S, Nishi K, Inoue H, Yoshie T, Kinoshita Y. Intern Med. 2010;49(12):1059-65. Epub 2010 Jun 15.


  875. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: Comparison of five staging systems
    Zhang XF, Qi X, Meng B, Liu C, Yu L, Wang B, Lv Y. Eur J Surg Oncol. 2010 Jun 8. [Epub ahead of print]


  876. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma
    Zhu AX. Expert Opin Investig Drugs. 2010 May;19(5):663-72.


  877. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort
    Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Radiology. 2010 Jun;255(3):955-65.


  878. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience
    Perrella A, Esposito C, Ioia G, Campanella L, Taglialatela D, Cuomo O. Transplant Proc. 2010 May;42(4):1226-8.


  879. High Expression of Macrophage Colony-Stimulating Factor-1 Receptor in Peritumoral Liver Tissue Is Associated with Poor Outcome in Hepatocellular Carcinoma After Curative Resection
    Jia JB, Wang WQ, Sun HC, Zhu XD, Liu L, Zhuang PY, Zhang JB, Zhang W, Xu HX, Kong LQ, Lu L, Wu WZ, Wang L, Tang ZY. Oncologist. 2010 Jun 15. [Epub ahead of print]


  880. Epidemiology, risk factors and surveillance of hepatocellular carcinoma
    Cabibbo G, Craxì A. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):352-5.


  881. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis
    Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH. Histopathology. 2010 May;56(6):683-93.


  882. Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old
    Colak D, Chishti MA, Al-Bakheet AB, Al-Qahtani A, Shoukri MM, Goyns MH, Ozand PT, Quackenbush J, Park BH, Kaya N. Mol Cancer. 2010 Jun 12;9(1):146. [Epub ahead of print]


  883. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy
    Wang FH, Yip YC, Zhang M, Vong HT, Chan KI, Wai KC, Wen JM. J Clin Pathol. 2010 May 24. [Epub ahead of print]


  884. Hepatocellular carcinoma in unrelated viral cirrhosis: long-term results after liver transplantation
    Lauterio A, Di Sandro S, Slim A, Giacomoni A, Mangoni I, Mihaylov P, Pirotta V, Aseni P, De Carlis L. Transplant Proc. 2010 May;42(4):1212-5.


  885. Expression profile reveals novel prognostic biomarkers in hepatocellular carcinoma
    Sun M, Wu G, Li Y, Fu X, Huang Y, Tang R, Guo Y, Qiu M, Mao Y, Zhao F, Li L, Huang S, Zhao X, Xie Y. Front Biosci (Elite Ed). 2010 Jun 1;2:829-40.


  886. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma
    Hessheimer AJ, Forner A, Varela M, Bruix J. Eur J Gastroenterol Hepatol. 2010 May 25. [Epub ahead of print]


  887. Molecularly targeted therapy in hepatocellular carcinoma
    Huynh H. Biochem Pharmacol. 2010 Apr 4. [Epub ahead of print]


  888. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int J Clin Oncol. 2010 Jun;15(3):235-41
    Tanaka S, Arii S. Epub 2010 May 27


  889. Novel inhibitors in development for hepatocellular carcinoma
    Wörns MA, Galle PR. Expert Opin Investig Drugs. 2010 May;19(5):615-29.


  890. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis
    Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, Liu CN, Zhong SX, Sang XT, Huang JF. World J Gastroenterol. 2010 Jun 21;16(23):2931-42.


  891. Prognostic Impact of Underlying Liver Fibrosis and Cirrhosis After Curative Resection of Hepatocellular Carcinoma
    Gassmann P, Spieker T, Haier J, Schmidt F, Mardin WA, Senninger N. World J Surg. 2010 Jun 11. [Epub ahead of print]


  892. Preoperative serum retinol-binding protein 4 is associated with the prognosis of patients with hepatocellular carcinoma after curative resection
    Wang DD, Zhao YM, Wang L, Ren G, Wang F, Xia ZG, Wang XL, Zhang T, Pan Q, Dai Z, Chen JP, Dai HY, Zhang W, He HW, Zhou JM, Tang GY, Zhou J, Fan J, Tang ZY. J Cancer Res Clin Oncol. 2010 Jun 15. [Epub ahead of print]


  893. Laparoscopic findings of reddish markings predict hepatocellular carcinoma in patients with hepatitis B virus-related liver disease
    Shoji B, Ikeda F, Fujioka SI, Kobashi H, Yasunaka T, Miyake Y, Shiraha H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. J Gastroenterol. 2010 Jun 12. [Epub ahead of print]


  894. Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma
    Kuroda H, Kasai K, Kakisaka K, Yasumi Y, Kataoka K, Ushio A, Miyamoto Y, Sawara K, Oikawa K, Kondo K, Miura Y, Endo R, Takikawa Y, Suzuki K. Hepatol Res. 2010 May;40(5):550-4.


  895. Laparoscopic ultrasound-guided radiofrequency ablation as a bridge to liver transplantation for hepatocellular carcinoma: preliminary results
    Panaro F, Piardi T, Audet M, Gheza F, Woehl-Jaegle ML, Portolani N, Cinqualbre J, Wolf P. Transplant Proc. 2010 May;42(4):1179-81.


  896. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital
    Qian MY, Yuwei J R, Angus P, Schelleman T, Johnson L, Gow P. J Gastroenterol Hepatol. 2010 May;25(5):951-6.


  897. Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma
    Welker MW, Zangos S, Kriener S, Mönch C, Zeuzem S, Trojan J. J Gastrointest Cancer. 2010 Jun;41(2):149-52.


  898. Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population
    Park MJ, Kim YS, Lee WJ, Lim HK, Rhim H, Lee J. Eur Radiol. 2010 Jun 19. [Epub ahead of print]


  899. Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation
    Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK. Jpn J Clin Oncol. 2010 May 21. [Epub ahead of print]


  900. A Single-Institute Experience with Sorafenib in Untreated and Previously Treated Patients with Advanced Hepatocellular Carcinoma
    Balsom SM, Li X, Trolli E, Rose J, Bloomston M, Patel T, Bekaii-Saab TS. Oncology. 2010 Apr 26;78(3-4):210-212. [Epub ahead of print]


  901. Sorafenib for the treatment of advanced hepatocellular carcinoma
    Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Health Technol Assess. 2010 May;14 Suppl 1:17-21.


  902. Hepatocellular carcinoma: occurrence, risk factors, biomarkers
    Fehér J, Lengyel G. Orv Hetil. 2010 Jun 6;151(23):933-40


  903. Downstaging of Hepatocellular Carcinoma Prior to Liver Transplant: Is There a Role for Adjuvant Sorafenib in Locoregional Therapy?
    Vagefi PA, Hirose R. J Gastrointest Cancer. 2010 May 5. [Epub ahead of print]


  904. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future
    Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Cancer Control. 2010 Apr;17(1):120-9.


  905. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Zhu AX. Ann Surg Oncol. 2010 May;17(5):1247-56. Epub 2010 Apr 20.


  906. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?
    Biolato M, Marrone G, Racco S, Di Stasi C, Miele L, Gasbarrini G, Landolfi R, Grieco A. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):356-62.


  907. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice
    Kudo M. Int J Clin Oncol. 2010 Jun;15(3):242-55. Epub 2010 May 28.


  908. Targeted therapies in hepatocellular carcinoma
    Bouattour M, Marijon H, Dreyer C, Faivre S, Raymond E. Presse Med. 2010 Apr 6. [Epub ahead of print]


  909. Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria
    Delis SG, Bakoyiannis A, Tassopoulos N, Athanassiou K, Kechagias A, Kelekis D, Madariaga J, Dervenis C. HPB (Oxford). 2009 Nov;11(7):551-8.


  910. Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation
    Vitale A, Volk ML, Gambato M, Zanus G, D'Amico F, Carraro A, Pauletto A, Bonsignore P, Scopelliti M, Polacco M, Russo F, Senzolo M, Burra P, Romano A, Angeli P, Cillo U. Transplant Proc. 2010 May;42(4):1194-6
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare
providers only. Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.